EP1313477A1 - Compounds and methods - Google Patents
Compounds and methodsInfo
- Publication number
- EP1313477A1 EP1313477A1 EP01958995A EP01958995A EP1313477A1 EP 1313477 A1 EP1313477 A1 EP 1313477A1 EP 01958995 A EP01958995 A EP 01958995A EP 01958995 A EP01958995 A EP 01958995A EP 1313477 A1 EP1313477 A1 EP 1313477A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- phenyl
- methoxyphenyl
- methoxy
- diisopropylamino
- methylethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 title claims description 124
- 238000000034 method Methods 0.000 title claims description 42
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 claims abstract description 30
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 claims abstract description 30
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 28
- 201000010099 disease Diseases 0.000 claims abstract description 27
- 238000011282 treatment Methods 0.000 claims abstract description 26
- 241000124008 Mammalia Species 0.000 claims abstract description 17
- 201000001320 Atherosclerosis Diseases 0.000 claims abstract description 13
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims abstract description 13
- 208000006673 asthma Diseases 0.000 claims abstract description 13
- 206010039073 rheumatoid arthritis Diseases 0.000 claims abstract description 12
- 208000012657 Atopic disease Diseases 0.000 claims abstract description 11
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract description 11
- 206010012438 Dermatitis atopic Diseases 0.000 claims abstract description 11
- 206010020751 Hypersensitivity Diseases 0.000 claims abstract description 11
- 230000007815 allergy Effects 0.000 claims abstract description 11
- 201000008937 atopic dermatitis Diseases 0.000 claims abstract description 11
- 201000006417 multiple sclerosis Diseases 0.000 claims abstract description 11
- 208000031886 HIV Infections Diseases 0.000 claims abstract description 10
- 208000037357 HIV infectious disease Diseases 0.000 claims abstract description 10
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims abstract description 10
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims abstract description 10
- 201000004681 Psoriasis Diseases 0.000 claims abstract description 10
- 230000003176 fibrotic effect Effects 0.000 claims abstract description 10
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims abstract description 10
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims abstract description 10
- 230000001404 mediated effect Effects 0.000 claims abstract description 10
- 210000000056 organ Anatomy 0.000 claims abstract description 10
- 201000000306 sarcoidosis Diseases 0.000 claims abstract description 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 267
- 239000001257 hydrogen Substances 0.000 claims description 196
- 229910052739 hydrogen Inorganic materials 0.000 claims description 196
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 147
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 90
- 229910052760 oxygen Inorganic materials 0.000 claims description 85
- 229910052757 nitrogen Inorganic materials 0.000 claims description 82
- 239000001301 oxygen Substances 0.000 claims description 80
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 78
- -1 C3. gcycloalkenyl Chemical group 0.000 claims description 65
- IVXQBCUBSIPQGU-UHFFFAOYSA-N piperazine-1-carboxamide Chemical compound NC(=O)N1CCNCC1 IVXQBCUBSIPQGU-UHFFFAOYSA-N 0.000 claims description 64
- 229910052717 sulfur Chemical group 0.000 claims description 61
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 48
- 125000003118 aryl group Chemical group 0.000 claims description 47
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 46
- 239000011593 sulfur Chemical group 0.000 claims description 46
- 150000002431 hydrogen Chemical group 0.000 claims description 41
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 39
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 34
- 125000005842 heteroatom Chemical group 0.000 claims description 34
- 229910052736 halogen Inorganic materials 0.000 claims description 33
- 150000002367 halogens Chemical class 0.000 claims description 33
- 239000000203 mixture Substances 0.000 claims description 30
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 24
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 22
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 22
- 125000000217 alkyl group Chemical group 0.000 claims description 20
- 125000001424 substituent group Chemical group 0.000 claims description 20
- 125000003341 7 membered heterocyclic group Chemical group 0.000 claims description 18
- 125000000623 heterocyclic group Chemical group 0.000 claims description 17
- 229920006395 saturated elastomer Polymers 0.000 claims description 15
- 125000004122 cyclic group Chemical group 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 14
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims description 12
- 125000004434 sulfur atom Chemical group 0.000 claims description 12
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 12
- HDCXQTPVTAIPNZ-UHFFFAOYSA-N n-({[4-(aminosulfonyl)phenyl]amino}carbonyl)-4-methylbenzenesulfonamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NC1=CC=C(S(N)(=O)=O)C=C1 HDCXQTPVTAIPNZ-UHFFFAOYSA-N 0.000 claims description 10
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 9
- 229910052799 carbon Inorganic materials 0.000 claims description 9
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 9
- 125000004043 oxo group Chemical group O=* 0.000 claims description 9
- 239000012453 solvate Substances 0.000 claims description 9
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 8
- 125000001072 heteroaryl group Chemical group 0.000 claims description 7
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 5
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 claims description 5
- 125000004423 acyloxy group Chemical group 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 claims description 3
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims description 3
- UHIQCWLCURIQPH-UHFFFAOYSA-N 4-(3-chlorophenyl)-n-[4-methoxy-3-(1-propan-2-ylpiperidin-4-yl)phenyl]piperazine-1-carboxamide Chemical compound C1=C(C2CCN(CC2)C(C)C)C(OC)=CC=C1NC(=O)N(CC1)CCN1C1=CC=CC(Cl)=C1 UHIQCWLCURIQPH-UHFFFAOYSA-N 0.000 claims description 3
- 150000001204 N-oxides Chemical class 0.000 claims description 3
- 125000002619 bicyclic group Chemical group 0.000 claims description 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 3
- WANWOJBOBGZDKW-UHFFFAOYSA-N n-[4-methoxy-3-(1-propan-2-ylpiperidin-4-yl)phenyl]-4-pyrazin-2-ylpiperazine-1-carboxamide Chemical compound C1=C(C2CCN(CC2)C(C)C)C(OC)=CC=C1NC(=O)N(CC1)CCN1C1=CN=CC=N1 WANWOJBOBGZDKW-UHFFFAOYSA-N 0.000 claims description 3
- 229910052700 potassium Inorganic materials 0.000 claims description 3
- UTWIEWFHLWROOA-UHFFFAOYSA-N 3-(1-cyclopentylpiperidin-4-yl)-4-methoxyaniline Chemical compound COC1=CC=C(N)C=C1C1CCN(C2CCCC2)CC1 UTWIEWFHLWROOA-UHFFFAOYSA-N 0.000 claims description 2
- WTHCGHOMPWBABT-UHFFFAOYSA-N 4-(3,5-dichlorophenyl)-n-[4-methoxy-3-(1-propan-2-ylpiperidin-4-yl)phenyl]piperazine-1-carboxamide Chemical compound C1=C(C2CCN(CC2)C(C)C)C(OC)=CC=C1NC(=O)N(CC1)CCN1C1=CC(Cl)=CC(Cl)=C1 WTHCGHOMPWBABT-UHFFFAOYSA-N 0.000 claims description 2
- WKRMEJICOBDSNT-UHFFFAOYSA-N 4-methoxy-3-(1-propan-2-ylpiperidin-4-yl)aniline Chemical compound COC1=CC=C(N)C=C1C1CCN(C(C)C)CC1 WKRMEJICOBDSNT-UHFFFAOYSA-N 0.000 claims description 2
- FUFZNHHSSMCXCZ-UHFFFAOYSA-N 5-piperidin-4-yl-3-[3-(trifluoromethyl)phenyl]-1,2,4-oxadiazole Chemical compound FC(F)(F)C1=CC=CC(C=2N=C(ON=2)C2CCNCC2)=C1 FUFZNHHSSMCXCZ-UHFFFAOYSA-N 0.000 claims description 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 2
- 101100219404 Mus musculus Calcrl gene Proteins 0.000 claims description 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 2
- DVGLHMZFPZWJGS-UHFFFAOYSA-N n-[3-(4-cyano-1-propan-2-ylpiperidin-4-yl)-4-methoxyphenyl]-4-(5,6,7,8-tetrahydronaphthalen-1-yl)piperazine-1-carboxamide Chemical compound COC1=CC=C(NC(=O)N2CCN(CC2)C=2C=3CCCCC=3C=CC=2)C=C1C1(C#N)CCN(C(C)C)CC1 DVGLHMZFPZWJGS-UHFFFAOYSA-N 0.000 claims description 2
- RVBLDTLTDGKIOU-UHFFFAOYSA-N n-[4-methoxy-3-(1-propan-2-ylpiperidin-4-yl)phenyl]-4-[2-methyl-3-(trifluoromethyl)phenyl]piperazine-1-carboxamide Chemical compound C1=C(C2CCN(CC2)C(C)C)C(OC)=CC=C1NC(=O)N(CC1)CCN1C1=CC=CC(C(F)(F)F)=C1C RVBLDTLTDGKIOU-UHFFFAOYSA-N 0.000 claims description 2
- 125000001624 naphthyl group Chemical group 0.000 claims description 2
- LWZJECQXMDQZCD-UHFFFAOYSA-N 2-(4-methoxyphenyl)-3-methylpiperazine-1-carboxamide Chemical compound C1=CC(OC)=CC=C1C1N(C(N)=O)CCNC1C LWZJECQXMDQZCD-UHFFFAOYSA-N 0.000 claims 1
- WLOXADCRGXCMRV-UHFFFAOYSA-N 4-(1h-indol-4-yl)-n-[4-methoxy-3-(1-propan-2-ylpiperidin-4-yl)phenyl]piperazine-1-carboxamide Chemical compound COC1=CC=C(NC(=O)N2CCN(CC2)C=2C=3C=CNC=3C=CC=2)C=C1C1CCN(C(C)C)CC1 WLOXADCRGXCMRV-UHFFFAOYSA-N 0.000 claims 1
- HPQYMQVJZWVUDP-UHFFFAOYSA-N 4-(2-chlorophenyl)-n-[4-methoxy-3-(1-propan-2-ylpiperidin-4-yl)phenyl]piperazine-1-carboxamide Chemical compound C1=C(C2CCN(CC2)C(C)C)C(OC)=CC=C1NC(=O)N(CC1)CCN1C1=CC=CC=C1Cl HPQYMQVJZWVUDP-UHFFFAOYSA-N 0.000 claims 1
- FAADVYVPNMLOLH-UHFFFAOYSA-N 4-(2-cyanophenyl)-n-[4-methoxy-3-(1-propan-2-ylpiperidin-4-yl)phenyl]piperazine-1-carboxamide Chemical compound C1=C(C2CCN(CC2)C(C)C)C(OC)=CC=C1NC(=O)N(CC1)CCN1C1=CC=CC=C1C#N FAADVYVPNMLOLH-UHFFFAOYSA-N 0.000 claims 1
- DDHRRRBBKQJRMS-UHFFFAOYSA-N 4-(3-chlorophenyl)piperazine-1-carboxamide Chemical compound C1CN(C(=O)N)CCN1C1=CC=CC(Cl)=C1 DDHRRRBBKQJRMS-UHFFFAOYSA-N 0.000 claims 1
- PTJCGDOULCFRFP-UHFFFAOYSA-N 4-(4-chlorophenyl)-4-hydroxy-n-[4-methoxy-3-(1-propan-2-ylpiperidin-4-yl)phenyl]piperidine-1-carboxamide Chemical compound C1=C(C2CCN(CC2)C(C)C)C(OC)=CC=C1NC(=O)N(CC1)CCC1(O)C1=CC=C(Cl)C=C1 PTJCGDOULCFRFP-UHFFFAOYSA-N 0.000 claims 1
- 125000004802 cyanophenyl group Chemical group 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 18
- 102000004274 CCR5 Receptors Human genes 0.000 abstract description 15
- 108010017088 CCR5 Receptors Proteins 0.000 abstract description 14
- 239000005557 antagonist Substances 0.000 abstract description 11
- 102000005962 receptors Human genes 0.000 abstract description 9
- 108020003175 receptors Proteins 0.000 abstract description 9
- 230000001225 therapeutic effect Effects 0.000 abstract description 8
- 230000007115 recruitment Effects 0.000 abstract description 4
- 150000001420 substituted heterocyclic compounds Chemical class 0.000 abstract description 4
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 abstract description 3
- 239000000556 agonist Substances 0.000 abstract description 3
- 230000006806 disease prevention Effects 0.000 abstract description 3
- 229940044551 receptor antagonist Drugs 0.000 abstract description 2
- 239000002464 receptor antagonist Substances 0.000 abstract description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical group C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 104
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 69
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 45
- 238000002360 preparation method Methods 0.000 description 45
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 23
- 239000000243 solution Substances 0.000 description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 20
- 102000001327 Chemokine CCL5 Human genes 0.000 description 18
- 108010055166 Chemokine CCL5 Proteins 0.000 description 18
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 16
- 239000004480 active ingredient Substances 0.000 description 16
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 14
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 11
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical group C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 11
- 210000001744 T-lymphocyte Anatomy 0.000 description 11
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 10
- 125000004432 carbon atom Chemical group C* 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 150000001448 anilines Chemical class 0.000 description 9
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Natural products C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 8
- 239000007788 liquid Substances 0.000 description 7
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 7
- 235000019341 magnesium sulphate Nutrition 0.000 description 7
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- BGTOWKSIORTVQH-UHFFFAOYSA-N cyclopentanone Chemical compound O=C1CCCC1 BGTOWKSIORTVQH-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- 239000012074 organic phase Substances 0.000 description 6
- 229910000027 potassium carbonate Inorganic materials 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 239000011369 resultant mixture Substances 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 5
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
- 238000011200 topical administration Methods 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 125000003545 alkoxy group Chemical group 0.000 description 4
- 239000012267 brine Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- FMKOJHQHASLBPH-UHFFFAOYSA-N isopropyl iodide Chemical compound CC(C)I FMKOJHQHASLBPH-UHFFFAOYSA-N 0.000 description 4
- 239000006210 lotion Substances 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 238000011321 prophylaxis Methods 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 239000007832 Na2SO4 Substances 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 239000003899 bactericide agent Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 210000004969 inflammatory cell Anatomy 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- DZNKOAWEHDKBEP-UHFFFAOYSA-N methyl 2-[6-[bis(2-methoxy-2-oxoethyl)amino]-5-[2-[2-[bis(2-methoxy-2-oxoethyl)amino]-5-methylphenoxy]ethoxy]-1-benzofuran-2-yl]-1,3-oxazole-5-carboxylate Chemical compound COC(=O)CN(CC(=O)OC)C1=CC=C(C)C=C1OCCOC(C(=C1)N(CC(=O)OC)CC(=O)OC)=CC2=C1OC(C=1OC(=CN=1)C(=O)OC)=C2 DZNKOAWEHDKBEP-UHFFFAOYSA-N 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 125000004430 oxygen atom Chemical group O* 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- 238000000825 ultraviolet detection Methods 0.000 description 3
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- KPUSZZFAYGWAHZ-UHFFFAOYSA-N 3-azabicyclo[2.2.2]octane Chemical group C1CC2CCC1NC2 KPUSZZFAYGWAHZ-UHFFFAOYSA-N 0.000 description 2
- SRAVSVBVHDLLPO-UHFFFAOYSA-N 4-(2-methoxyphenyl)piperidine Chemical compound COC1=CC=CC=C1C1CCNCC1 SRAVSVBVHDLLPO-UHFFFAOYSA-N 0.000 description 2
- RUBROIIGKQNJPQ-UHFFFAOYSA-N 4-hydroxypiperidine-1-carboxamide Chemical compound NC(=O)N1CCC(O)CC1 RUBROIIGKQNJPQ-UHFFFAOYSA-N 0.000 description 2
- SODWJACROGQSMM-UHFFFAOYSA-N 5,6,7,8-tetrahydronaphthalen-1-amine Chemical compound C1CCCC2=C1C=CC=C2N SODWJACROGQSMM-UHFFFAOYSA-N 0.000 description 2
- ODWVFJUVKLPMDM-UHFFFAOYSA-N 9-methyl-9-azabicyclo[3.3.1]nonane Chemical group C1CCC2CCCC1N2C ODWVFJUVKLPMDM-UHFFFAOYSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 235000003911 Arachis Nutrition 0.000 description 2
- 244000105624 Arachis hypogaea Species 0.000 description 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 2
- 108010012236 Chemokines Proteins 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical group C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 2
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 2
- QQONPFPTGQHPMA-UHFFFAOYSA-N Propene Chemical group CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical group C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 description 2
- 210000003651 basophil Anatomy 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 2
- 230000001275 ca(2+)-mobilization Effects 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 210000003979 eosinophil Anatomy 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000002825 functional assay Methods 0.000 description 2
- 239000000417 fungicide Substances 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 125000002346 iodo group Chemical group I* 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 239000000865 liniment Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- FDPIMTJIUBPUKL-UHFFFAOYSA-N pentan-3-one Chemical group CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical group C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 229940075993 receptor modulator Drugs 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
- XLRPYZSEQKXZAA-OCAPTIKFSA-N tropane Chemical group C1CC[C@H]2CC[C@@H]1N2C XLRPYZSEQKXZAA-OCAPTIKFSA-N 0.000 description 2
- 229930004006 tropane Chemical group 0.000 description 2
- QPYBDSZALQPZTI-UHFFFAOYSA-N (2,2,2-trifluoroacetyl) 2,2,2-trifluoroacetate;2,2,2-trifluoro-1-[4-(2-methoxyphenyl)piperidin-1-yl]ethanone Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F.COC1=CC=CC=C1C1CCN(C(=O)C(F)(F)F)CC1 QPYBDSZALQPZTI-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- HAKSOKWVNPZVNM-UHFFFAOYSA-N 1,2,3,4-tetrahydropyridine;hydrochloride Chemical compound Cl.C1CNC=CC1 HAKSOKWVNPZVNM-UHFFFAOYSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- VNICFCQJUVFULD-UHFFFAOYSA-N 1-(1-naphthalenyl)piperazine Chemical compound C1CNCCN1C1=CC=CC2=CC=CC=C12 VNICFCQJUVFULD-UHFFFAOYSA-N 0.000 description 1
- PWZDJIUQHUGFRJ-UHFFFAOYSA-N 1-(2-chlorophenyl)piperazine Chemical compound ClC1=CC=CC=C1N1CCNCC1 PWZDJIUQHUGFRJ-UHFFFAOYSA-N 0.000 description 1
- SFLNVAVCCYTHCQ-UHFFFAOYSA-N 1-(3,4-dimethylphenyl)piperazine Chemical compound C1=C(C)C(C)=CC=C1N1CCNCC1 SFLNVAVCCYTHCQ-UHFFFAOYSA-N 0.000 description 1
- LISGMSBYRAXPJH-UHFFFAOYSA-N 1-(3,5-dichlorophenyl)piperazine Chemical compound ClC1=CC(Cl)=CC(N2CCNCC2)=C1 LISGMSBYRAXPJH-UHFFFAOYSA-N 0.000 description 1
- PZIBVWUXWNYTNL-UHFFFAOYSA-N 1-(3-methoxyphenyl)piperazine Chemical compound COC1=CC=CC(N2CCNCC2)=C1 PZIBVWUXWNYTNL-UHFFFAOYSA-N 0.000 description 1
- FOAUOTNKXGVFRU-UHFFFAOYSA-N 1-[2-methyl-3-(trifluoromethyl)phenyl]piperazine Chemical compound C1=CC=C(C(F)(F)F)C(C)=C1N1CCNCC1 FOAUOTNKXGVFRU-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- UJFAGUWJTHAHJO-UHFFFAOYSA-N 1-cyclopentyl-4-(2-methoxy-5-nitrophenyl)piperidine Chemical compound COC1=CC=C([N+]([O-])=O)C=C1C1CCN(C2CCCC2)CC1 UJFAGUWJTHAHJO-UHFFFAOYSA-N 0.000 description 1
- LLSKXGRDUPMXLC-UHFFFAOYSA-N 1-phenylpiperidine Chemical class C1CCCCN1C1=CC=CC=C1 LLSKXGRDUPMXLC-UHFFFAOYSA-N 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- ONOBXDPYDHTSBQ-UHFFFAOYSA-N 2,3,4,7-tetrahydro-1h-diazepine Chemical compound C1CC=CCNN1 ONOBXDPYDHTSBQ-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- YMDZDFSUDFLGMX-UHFFFAOYSA-N 2-chloro-n-(2-chloroethyl)ethanamine;hydron;chloride Chemical compound [Cl-].ClCC[NH2+]CCCl YMDZDFSUDFLGMX-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- VSWICNJIUPRZIK-UHFFFAOYSA-N 2-piperideine Chemical compound C1CNC=CC1 VSWICNJIUPRZIK-UHFFFAOYSA-N 0.000 description 1
- CYASANLJWAJEPW-UHFFFAOYSA-N 2-piperidin-4-yl-1,3-benzothiazole Chemical compound C1CNCCC1C1=NC2=CC=CC=C2S1 CYASANLJWAJEPW-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- FTAHXMZRJCZXDL-UHFFFAOYSA-N 3-piperideine Chemical group C1CC=CCN1 FTAHXMZRJCZXDL-UHFFFAOYSA-N 0.000 description 1
- RUALGAYGCNCJRR-UHFFFAOYSA-N 4-(2-chlorophenyl)piperazine-1-carboxamide Chemical compound C1CN(C(=O)N)CCN1C1=CC=CC=C1Cl RUALGAYGCNCJRR-UHFFFAOYSA-N 0.000 description 1
- AWBVJVXZKYXUBF-UHFFFAOYSA-N 4-(3,4-dichlorophenyl)-n-[4-methoxy-3-(1-propan-2-ylpiperidin-4-yl)phenyl]piperazine-1-carboxamide Chemical compound C1=C(C2CCN(CC2)C(C)C)C(OC)=CC=C1NC(=O)N(CC1)CCN1C1=CC=C(Cl)C(Cl)=C1 AWBVJVXZKYXUBF-UHFFFAOYSA-N 0.000 description 1
- APBDKYHKEZOVSE-UHFFFAOYSA-N 4-(4-chlorophenyl)piperazine-1-carboxamide Chemical compound C1CN(C(=O)N)CCN1C1=CC=C(Cl)C=C1 APBDKYHKEZOVSE-UHFFFAOYSA-N 0.000 description 1
- YXKKMSUXTVDHSI-UHFFFAOYSA-N 4-[4-chloro-3-(trifluoromethyl)phenyl]-n-[4-methoxy-3-(1-propan-2-ylpiperidin-4-yl)phenyl]piperazine-1-carboxamide Chemical compound C1=C(C2CCN(CC2)C(C)C)C(OC)=CC=C1NC(=O)N(CC1)CCN1C1=CC=C(Cl)C(C(F)(F)F)=C1 YXKKMSUXTVDHSI-UHFFFAOYSA-N 0.000 description 1
- UTBULQCHEUWJNV-UHFFFAOYSA-N 4-phenylpiperidine Chemical compound C1CNCCC1C1=CC=CC=C1 UTBULQCHEUWJNV-UHFFFAOYSA-N 0.000 description 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 description 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 101100295741 Gallus gallus COR4 gene Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 229920000715 Mucilage Polymers 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 229910003827 NRaRb Inorganic materials 0.000 description 1
- 229910020889 NaBH3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 229940122828 Oxytocin receptor antagonist Drugs 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 101001086866 Sus scrofa Pulmonary surfactant-associated protein B Proteins 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- DDSZWBCJXDRQDU-UHFFFAOYSA-N [N].C1CCNCC1 Chemical group [N].C1CCNCC1 DDSZWBCJXDRQDU-UHFFFAOYSA-N 0.000 description 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000010936 aqueous wash Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- IUKQLMGVFMDQDP-UHFFFAOYSA-N azane;piperidine Chemical compound N.C1CCNCC1 IUKQLMGVFMDQDP-UHFFFAOYSA-N 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000003067 chemokine receptor CCR5 antagonist Substances 0.000 description 1
- 239000005482 chemotactic factor Substances 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 229960002152 chlorhexidine acetate Drugs 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- QOPVNWQGBQYBBP-UHFFFAOYSA-N chloroethyl chloroformate Chemical compound CC(Cl)OC(Cl)=O QOPVNWQGBQYBBP-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 125000002720 diazolyl group Chemical group 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- IVQHKNGTRPZOJK-UHFFFAOYSA-L dipotassium;4-(2-methoxy-5-nitrophenyl)piperidine;carbonate Chemical compound [K+].[K+].[O-]C([O-])=O.COC1=CC=C([N+]([O-])=O)C=C1C1CCNCC1 IVQHKNGTRPZOJK-UHFFFAOYSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- MFHSHQIHYPPRMQ-UHFFFAOYSA-N ethyl 3-piperazin-1-ylbenzoate Chemical compound CCOC(=O)C1=CC=CC(N2CCNCC2)=C1 MFHSHQIHYPPRMQ-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000010265 fast atom bombardment Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 150000003951 lactams Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-L malate(2-) Chemical compound [O-]C(=O)C(O)CC([O-])=O BJEPYKJPYRNKOW-UHFFFAOYSA-L 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000003584 mesangial cell Anatomy 0.000 description 1
- 229940071648 metered dose inhaler Drugs 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 230000000802 nitrating effect Effects 0.000 description 1
- 238000006396 nitration reaction Methods 0.000 description 1
- FJJUXLIDBQYLHZ-UHFFFAOYSA-N nitric acid;2,2,2-trifluoro-1-[4-(2-methoxy-5-nitrophenyl)piperidin-1-yl]ethanone Chemical compound O[N+]([O-])=O.COC1=CC=C([N+]([O-])=O)C=C1C1CCN(C(=O)C(F)(F)F)CC1 FJJUXLIDBQYLHZ-UHFFFAOYSA-N 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- UNEIHNMKASENIG-UHFFFAOYSA-N para-chlorophenylpiperazine Chemical compound C1=CC(Cl)=CC=C1N1CCNCC1 UNEIHNMKASENIG-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000005561 phenanthryl group Chemical group 0.000 description 1
- PDTFCHSETJBPTR-UHFFFAOYSA-N phenylmercuric nitrate Chemical compound [O-][N+](=O)O[Hg]C1=CC=CC=C1 PDTFCHSETJBPTR-UHFFFAOYSA-N 0.000 description 1
- YZTJYBJCZXZGCT-UHFFFAOYSA-N phenylpiperazine Chemical group C1CNCCN1C1=CC=CC=C1 YZTJYBJCZXZGCT-UHFFFAOYSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- MCSINKKTEDDPNK-UHFFFAOYSA-N propyl propionate Chemical compound CCCOC(=O)CC MCSINKKTEDDPNK-UHFFFAOYSA-N 0.000 description 1
- 230000001185 psoriatic effect Effects 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 238000001525 receptor binding assay Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 102000003702 retinoic acid receptors Human genes 0.000 description 1
- 108090000064 retinoic acid receptors Proteins 0.000 description 1
- XMVJITFPVVRMHC-UHFFFAOYSA-N roxarsone Chemical group OC1=CC=C([As](O)(O)=O)C=C1[N+]([O-])=O XMVJITFPVVRMHC-UHFFFAOYSA-N 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 150000003413 spiro compounds Chemical class 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000005306 thianaphthenyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 150000003571 thiolactams Chemical class 0.000 description 1
- 125000000464 thioxo group Chemical group S=* 0.000 description 1
- 230000003195 tocolytic effect Effects 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- ZMCBYSBVJIMENC-UHFFFAOYSA-N tricaine Chemical group CCOC(=O)C1=CC=CC(N)=C1 ZMCBYSBVJIMENC-UHFFFAOYSA-N 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
- C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
- C07D211/64—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4 having an aryl radical as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
Definitions
- This invention relates to substituted heterocyclic compounds which are modulators, agonists or antagonists, of the CC chemokine receptor CC-CKR5 now designated as CCR5 (Nature Medicine 1996, 2, 1174-8).
- this invention relates to the treatment and prevention of disease states mediated by CCR5.
- T cells are not only key regulators of the immune response to infectious agents but are believed critical for the initiation and maintenance of the inflammatory reaction in a variety of chronic diseases.
- Increased numbers or enhanced activation state of T cells, especially CD4+ T cells have been demonstrated in the synovium of individuals with rheumatoid arthritis (MJ. Elliott and R. N. Maini, Int. Arch. Allergy Immunol. 104: 112-1125, 1994), in the bronchial mucosa of asthmatics (C.J. Corrigan and A.B. Kay, Immunol. Today 13:501-506, 1992), in the lesions of multiple sclerosis (R. Martin and H. F. McFarland, Grit. Rev. Clin. Lab. Sci.
- T cells as well as other inflammatory cells, will migrate into tissues in response to the production of a variety of chemotactic factors.
- chemokines a superfamily of 8-12 kDa proteins known as the chemokines. These proteins share structural features such as the presence of 3-4 conserved cysteine residues.
- RANTES which stands for Regulated upon Activation Normal T cell Expressed and Secreted, is an 8 kDa protein member of CC branch of the chemokine family. These proteins recruit and activate immune and inflammatory cells through an interaction with G- protein coupled receptors.
- the CC branch is defined by the absence of an intervening amino acid residue between the first two cysteine residues and members of this family predominately elicit the migration of mononuclear cells, eosinophils and basophils (M. Baggiolini, B. Dewald, and B. Moser, Adv. Immunol. 55: 97-179, 1994; and J.J. Oppenheim, C.O.C. Zachariae, N. Mukaida, and K. Matsushima, Annu. Rev. Immunol. 9: 617-648, 1991).
- RANTES potently produces chemotaxis of T cells, basophils, eosinophils, monocytes and mast cells.
- RANTES was originally identified as gene product induced late after antigen activation of T-cells (TJ. Schall, J. Jongstra, BJ. Dyer, J. Jorgensen, et al., J. Immunol. 141:1018-1025, 1988), however, RANTES has been shown to be synthesized and secreted by a diverse group of cells that include epithelial and endothelial cells (C. Stellato, L.A. Beck, G.A. Gorgone, D. Proud, et al., J. Immunol. 155: 410-418, 1995; and A. Marfaing-Koka, O. Devergne, G. Gorgone, A. Portier, et al, J.
- RANTES mRNA is rapidly upregulated in response to IL-1 or TNF « .
- RANTES mRNA is not usually detected in normal tissues (J.M. Pattison, P. J. Nelson, and A.M. Krensky, Clin. Immunofher. 4: 1-8, 1995), increased mRNA or protein has been found in diseases characterized by a mononuclear infiltrate.
- RANTES mRNA was visualized using in situ hybridization in renal allografts undergoing rejection (J.M. Pattison, P.J. Nelson, and A.M.
- CCR5 when expressed in either HEK 293 cells or CHO cells, binds RANTES.
- This receptor is expressed in T-cells and in monocytes and macrophages, immune/inflammatory cells which are important in the maintenance of a chronic inflammatory reaction.
- CCR5 Pharmacological characterization of CCR5 indicates similarities to the RANTES binding site observed on isolated T cells. Therefore, antagonism of RANTES' action on CCR5, as well as antagonism of other natural modulators of CCR5, should inhibit the recruitment and activation of T cells and macrophages into inflammatory lesions and provide a novel therapeutic approach for the treatment of atopic and autoimmune disorders.
- T cells express CCR5, selective receptor modulators of CCR5, particularly antagonists, are likely to provide beneficial effects in diseases including, but not limited to, asthma and atopic disorders (for example, atopic dermatitis and allergies), rheumatoid arthritis, sarcoidosis, or idiopathic pulmonary fibrosis and other fibrotic diseases, atherosclerosis, psoriasis, autoimmune diseases such as multiple sclerosis, treating and/or preventing rejection of transplanted organs, and inflammatory bowel disease, all in mammals, preferably humans.
- atopic disorders for example, atopic dermatitis and allergies
- sarcoidosis for example, atopic dermatitis and allergies
- idiopathic pulmonary fibrosis and other fibrotic diseases for example, atherosclerosis, psoriasis, autoimmune diseases such as multiple sclerosis, treating and/or preventing rejection of transplanted organs, and inflammatory bowel disease, all in mammals, preferably humans.
- CCR5 may play a role in their recruitment and therefore antagonists to CCR5 could provide potential therapeutic activity in the treatment of COPD. Also, since CCR5 is a co- receptor for the entry of HIV into cells, selective receptor modulators may be useful in the treatment of HIV infection.
- the present invention is to compounds of formula (I), or a pharmaceutically acceptable salt, or solvate thereof, and their use as CCR5 modulators for the treatment and/or prophylaxis of certain disease states, including, but not limited to, COPD, asthma and atopic disorders (for example, atopic dermatitis and allergies), rheumatoid arthritis, sarcoidosis, or idiopathic pulmonary fibrosis and other fibrotic diseases, atherosclerosis, psoriasis, autoimmune diseases such as multiple sclerosis, treating and/or preventing rejection of transplanted organs, inflammatory bowel disease, and HIV infection, all in mammals, preferably humans.
- COPD COPD
- asthma and atopic disorders for example, atopic dermatitis and allergies
- rheumatoid arthritis for example, atopic dermatitis and allergies
- sarcoidosis or idiopathic pulmonary fibrosis and other fibrotic diseases
- atherosclerosis p
- the preferred compounds for use as CCR5 modulators are those compounds of Formula (I) as noted herein.
- the present invention is directed to a method of preventing or treating CCR5-mediated diseases in a mammal, preferably a human, by administering to the mammal an effective amount of a CCR5 receptor ligand, or a pharmaceutically acceptable salt or solvate thereof.
- the present invention is directed to methods for making and using the compounds of formula (I), as well as pharmaceutical compositions of formula (I) or a pharmaceutically acceptable salts or solvates thereof.
- the present invention is directed to the use of a CCR5 receptor ligand in the manufacture of a medicament for the prophylaxis or treatment of certain disease states, including, but not limited to, COPD, asthma and atopic disorders (for example, atopic dermatitis and allergies), rheumatoid arthritis, sarcoidosis, or idiopathic pulmonary fibrosis and other fibrotic diseases, atherosclerosis, psoriasis, autoimmune diseases such as multiple sclerosis, treating and/or preventing rejection of transplanted organs, inflammatory bowel disease, and HIV infection, for example in a mammal such as a human.
- COPD COPD
- asthma and atopic disorders for example, atopic dermatitis and allergies
- rheumatoid arthritis for example, atopic dermatitis and allergies
- sarcoidosis for example, atopic dermatitis and allergies
- idiopathic pulmonary fibrosis and other fibrotic diseases
- the present invention is directed to a CCR5 receptor ligand, or a pharmaceutically acceptable salt, or solvate thereof, for use in the prophylaxis or treatment of certain disease states, including, but not limited to, COPD, asthma and atopic disorders (for example, atopic dermatitis and allergies), rheumatoid arthritis, sarcoidosis, or idiopathic pulmonary fibrosis and other fibrotic diseases, atherosclerosis, psoriasis, autoimmune diseases such as multiple sclerosis, treating and/or preventing rejection of transplanted organs, inflammatory bowel disease, and HIV infection, for example in a mammal such as a human.
- COPD COPD
- asthma and atopic disorders for example, atopic dermatitis and allergies
- rheumatoid arthritis for example, atopic dermatitis and allergies
- sarcoidosis or idiopathic pulmonary fibrosis and other fibrotic diseases
- atherosclerosis
- the present invention is also directed to combined therapy to prevent and treat inflammatory and immunoregulatory disorders or diseases, including asthma and allergic diseases, as well as rheumatoid arthritis and atherosclerosis, and those pathologies noted above, and is illustrated by the combination of the compounds of this invention and other compounds which are know for such utilities.
- the present invention is further directed to combinations of the present compounds of formula (I) with one or more agents useful in the prevention or treatment of AIDS.
- the compounds of this invention may be effectively administered, whether at periods of pre-exposure and/or post-exposure, in combination with effective amounts of the AIDS antivirals, immunomodulators, anti-infectives, or vaccines known to the skilled artisan.
- substituted heterocycles of formula (I) are CCR5 receptor modulators. It has also now been discovered that selective inhibition of CCR5 receptor mechanisms by treatment with the receptor modulators of formula (I), or a pharmaceutically acceptable salt thereof, represents a novel therapeutic and preventative approach to the treatment of a variety of disease states, including, but not limited to, asthma and atopic disorders (for example, atopic dermatitis and allergies), rheumatoid arthritis, sarcoidosis, or idiopathic pulmonary fibrosis and other fibrotic diseases, atherosclerosis, psoriasis, autoimmune diseases such as multiple sclerosis, treating and/or preventing rejection of transplanted organs, and inflammatory bowel disease, all in mammals, preferably humans.
- atopic disorders for example, atopic dermatitis and allergies
- sarcoidosis or idiopathic pulmonary fibrosis and other fibrotic diseases
- atherosclerosis psoriasis
- autoimmune diseases such as multiple
- CCR5 may play a role in their recruitment and therefore antagonists to CCR5 could provide potential therapeutic in the treatment of COPD. Also, since CCR5 is a co-receptor for entry into cells, selective receptor modulators may be useful in the treatment of HIV infection.
- CCR5 modulators include those compounds as described in FR 2758328, published 17 July 1998, FR 2761069, published 25 September 1998, WO 94/07496, published 14 April 1994, WO 95/25443, published 28 September 1995, and PCT/USOO/01908, filed January 25, 2000. Each of these references is incorporated herein in their entirety.
- Preferred compounds for use as CCR5 modulators are those compounds of formula (I) as noted herein.
- a preferred group of compounds for use herein are those compounds of the formula (I) or a pharmaceutically acceptable salt or solvate thereof:
- A' is aryl or heteroaryl, each of which is optionally substituted with one or more of R! '; or A' is aryl or heteroaryl fused to a saturated or partly unsaturated 5-7- membered ring to form a higher order ring moiety, which ring moiety optionally contains 1 or 2 heteroatoms selected from oxygen, nitrogen or sulfur, wherein nitrogen may be optionally substituted with hydrogen, Ci.gaikyl or C3_7cycloalkyl; wherein the higher order ring moiety is optionally substituted with one or more of R! ;
- Rl' is hydrogen, Cj.galkyl, C2_6alkenyl, C2-6alkynyl, C3_7cycloalkyl, C3_ 6 cycloalkenyl, CH 2 CF 3 , aryl, aralkyl, (CH 2 ) a 'NR 2 'R 3 ', (CH2) a 'N 2 'COR4', (CH2)a'NR 2 'CO 2 R 5 ', (CH 2 ) a 'NR 2 'SO2R 6 ', (CH 2 ) a €ONR 7 'R 8 ', hydroxyC 1 _ 6 alkyl, C ⁇ _4alkoxyalkyl (optionally substituted by a C j ⁇ alkoxy or hydroxy group), (CH 2 ) a CO 2 C ⁇ .
- R 1 ' is a 5- to 7-membered ring containing 1 to 4 heteroatoms selected from nitrogen, oxygen, or sulfur, optionally substituted with hydrogen, C ⁇ . ⁇ alkyl, C3_7cycloalkyl, C3_6cycloalkenyl, hydroxyCi ⁇ galkyl, (C _ 6a ⁇ kyl)C ⁇ _6alkyl, C0NR 7 'R 8 ', CO2R 17 ', cyano, aryl, trifluoromethyl, nitro, hydroxy, C ⁇ _galkoxy, acyloxy, or halogen; a' is 1, 2, 3 or 4; b' is 0, 1, 2 or 3; c'is 1, 2 or 3;
- R 2 ' and R 3 ' are independently hydrogen or C ⁇ _6alkyl, or R 2 ' and R 3 together with the nitrogen to which they are attached, form a 5- to 6-membered heterocyclic ring which ring may be optionally substituted by an oxo group, or, when there are 6 ring members, the ring may optionally contain one oxygen or one sulfur atom;
- R4' is hydrogen, C ⁇ galkyl or C ⁇ alkoxy alkyl, or, when Rl'is NR 'C0R4', R4' is (CH2) ⁇ _3 and forms a ring with A';
- R 5 ' is C ⁇ _6alkyl;
- R ⁇ ' is C ⁇ _6alkyl or phenyl;
- R 7 ' and R 8 ' are independently hydrogen or C ⁇ _6alkyl, or R 7 ' and R 8 together with the nitrogen to which they are attached form a 5- to 6-membered saturated heterocyclic ring, wherein when there are 6 ring members, the ring may optionally contain one oxygen or one sulfur atom;
- R ⁇ ' is C j ⁇ alkyl, optionally substituted by a C ⁇ _6alkoxy;
- RlO' and R* 1 are independently hydrogen or Chalky!;
- R l2 ' is hydrogen or Ci. ⁇ aikyi;
- R ⁇ - 3 ' is hydrogen or C ⁇ _6alkyl;
- Rl4' and R ⁇ ' are independently hydrogen or Chalky!
- R 1 ⁇ ' is hydrogen or Ci.galkyl
- R* 7 ' is hydrogen or C ⁇ _6alkyl optionally substituted with one or more substituents selected from C j _galkyl, C j ⁇ alkoxy, hydroxy, or NR 2 R 3 ';
- R i8 ' and R ⁇ 9 are independently hydrogen or C ⁇ alkyl;
- R 0' and R 2x ' are independently hydrogen or C j .galkyl, or R 2 ⁇ ' and R 21 ' together with the nitrogen to which they are attached form a 5- to 6-membered saturated heterocyclic ring which, when the ring is 6-membered, may optionally contain in the ring one oxygen or one sulfur atom.
- R 22 ' is hydrogen or C ⁇ .galkyl;
- CR 4 ' CR 24 CO, C ⁇ CCO, (C(R 24 ') 2 ) c "SO 2 , SO 2 [C(R 24 ') 2 ] a » , NR 2 5 , [C(R 2 4 , ) 2 ] a --SO2, NR 2 5'sO 2 [C(R 24 ') 2 ] a -'SO 2 , O[C(R 24 ') 2 ] a "SO 2 , SO 2 NR 2 5'[C(R 4') 2 ] 1 _ 2 , [C(R 24 ') 2 ] b »COO[C(R 24 ') 2 ] 2 , [C(R 2 4') 2 ] b HCONR 2 5'[C(R 2 4') 2 ] 1 .
- D' may further be O, NR 25 ', CONR 25 ', SO 2 NR 25 ', OCONR 25 ', NR25'C00, NR 25 'CONR 25 ', [C(R 2 4') 2 ] a "NR 25 '[C(R 2 4') 2 ] b .., [C(R 2 4')2] a --O[C(R 24 ')2]b", CO[C(R 4')2] a »NR 2 5', NR 5'[C(R 2 4') 2 ] a »O, NR 25' [C( R24' )2]aêt NR 25' j O[C(R 4') 2 ] a »O, CO[C(R 24 ') 2 ] a »O, SO 2 [C(R 24 ') 2 ] a ->NR 2 5
- R 24 ' is hydrogen or C ⁇ galkyl;
- R 2 ⁇ ' is hydrogen or Cj.galkyl;
- R 2 ⁇ ' is hydrogen or Cj ⁇ galkyl
- R 27 ' is hydrogen, OR 28 ', NHR 28 ', CN, NO 2 , R 28 ', SR 29 ', COR 28 ', CHOHR 28 ', CO 2 R 28 ', NHCOR 28 ', NHCO 2 R 29 ', NHSO 2 R 29 ', or OCONHR 28 ';
- R 2 ' is hydrogen, C ⁇ _5alkyl, aryl or aralkyl
- R 29 is C ⁇ _5alkyl, aryl or aralkyl
- R' is one or more of hydrogen or Cj_6alkyl, or R' is oxo;
- J' is CO or SO 2 ;
- L' is NR 3 0', O or C(R 30 ') 2 ;
- R 3 ⁇ is hydrogen or C ⁇ galkyl; E represents a group (a):
- R 1 and R 2 are independently hydrogen or C ⁇ _6alkyl; alternatively B(CR i R 2 ) a is OCR 1 R 2 CR 1 (OH)CR 1 R 2 or OCR 1 R2CR 1 (OCOCH 3 )CR 1 R2;
- R 3 and R 4 are independently hydrogen, C ⁇ _6alkyl, C3_7cycloalkyl, aralkyl, or together with the nitrogen atom to which they are attached form an optionally substituted 5- to 7-membered heterocyclic ring which may contain an additional heteroatom selected from oxygen, nitrogen or sulfur, where optional substituents include C ⁇ _ 6 alkyl, aryl, CONR 1 ⁇ 11 , NR 10 R n , hydroxy, OCOR 12 , NHCOCF3,
- NHCOC 0 -6alkyl wherein the alkyl of NHCOC 0 -6alkyl is optionally substituted by OH;
- R 5 is hydrogen, Chalky!, aryl, CN, CONR 15 R 16 , CO 2 R 17 , trifluoromethyl, NHCO 2 R 18 , hydroxy, Ci.galkoxy, benzyloxy, OCH ⁇ O ⁇ .galkyl, OCF3, S(O) d R 19 , SO 2 NR 20 R 21 or halogen;
- R 9 is hydrogen, Ci.gaikyl, or phenyrC ⁇ _6alkyl
- R 13 , R 14 , R 18 , and R 19 are independently Ci ⁇ alkyl; a is 1, 2, 3, or 4; b is 1 or 2; c and d are independently 0, 1 or 2; e is 2, 3 or 4; f is O, 1, 2 or 3; alternatively, E represents a group (b):
- R 3 ⁇ is hydrogen, C ⁇ galkyl, or C3_7cycloalkyl
- J is oxygen, CR 36 R 37 , or NR 38 , or J is a group
- R 34 , R 35 , R 36 , R 37 , and R 38 are independently hydrogen or Cj.galkyl; g is 1, 2 or 3; h is 1, 2 or 3; i is 2, 3, or 4; j is 0, 1, 2, or 3; k is 0, 1 or 2; alternatively, E represents a group (c):
- R 39 and R 4 ⁇ are independently hydrogen or Cj.galkyl;
- R 41 is a group of formula (d):
- R 4i is a group of formula (e):
- R 42 is hydrogen, Cx.galkyl, aryl, CN, CONR 48 R 49 , CO 2 R 50 , trifluoromethyl, NHCO 2 R 51 , hydroxy, C ⁇ _ 6 alkoxy, benzyloxy, OCF 3 , S(O) s R 52 , SO 2 NR 53 R 54 , or halogen;
- R 47 is hydrogen, C ⁇ galkyl, or C3_7 cycloalkyl
- R ⁇ l and R ⁇ 2 are independently C ⁇ _6alkyl; 1 is 0, 1, 2, or 3; m is 1 or 2; n is O, 1, or 2 o, p, and q are independently integers having the value 1, 2, or 3; r is 0,1, 2, or 3; s is 0, 1, or 2; t is 2 or 3; alternatively, E represents a group (f):
- R ⁇ 7 and R ⁇ 8 are independently hydrogen or C ⁇ _galkyl;
- R ⁇ 9 and R ⁇ 0 are independently hydrogen, C ⁇ .galkyl, C3_7cycloalkyl, aralkyl, or together with the nitrogen atom to which they are attached form an optionally substituted 5- to 7-membered heterocyclic ring which may contain an additional heteroatom selected from oxygen, nitrogen or sulfur, where optional substituents include C ⁇ alkyl, aryl, CONR 61 R 62 , NR 61 R 62 , hydroxy, OCOR 63 , NHCOCF3, NHSO 2 R 64 NHCO 2 R 65 , or NHCOC 0 -6alkyl wherein the alkyl of NHCOC 0 -6alkyl is optionally substituted by OH;
- T is -(CR66 R 67) V . or -0(CR66R67) W . ;
- R ⁇ 4 and R ⁇ 5 ⁇ e independently C ⁇ _6alkyl; u is 1 to 4; v is 2 or 3; w is 1, 2, or 3; x is 0, 1 or 2; alternatively, E represents a group (g):
- R 7i is a 5- to 7-membered saturated or partially saturated heterocyclic ring containing a nitrogen atom and optionally a further 1 or 2 heteroatoms selected from nitrogen, oxygen or sulfur or R 7 is an optionally substituted 6,6 or 6,5 bicyclic ring containing a nitrogen atom and optionally a further heteroatom selected from oxygen, nitrogen or sulfur, which ring systems may be optionally substituted with one or more of C ⁇ alkyl and optionally substituted on nitrogen with hydrogen, Cj.galkyl or C3_ 7cycloalkyl;
- R 72 is hydrogen, C ⁇ alkyl, aryl, CN, CONR 74 R 7 5, CO2R 76 , trifluoromethyl, NHCO 2 R 77 , hydroxy, Cj ⁇ alkoxy, benzyloxy, OCH 2 CO 2 C ⁇ _6alkyl, OCF3, S(O) z R 78 , SO 2 NR 79 R 80 , or halogen;
- R 74 , R 75 , R 76 , R 79 , R 80 , R 81 , and R 82 are independently hydrogen or Cj_ g ⁇ kyl;
- R 77 and R 78 are independently C ⁇ alkyl; y is 1 or 2; z is 0, 1, or 2; aa is 2, 3 or 4; ab is O, 1, 2 or 3; alternatively, E represents a group (h):
- R 83 and R 84 are independently hydrogen or C j .galkyl;
- R ⁇ nd R 8 ⁇ are independently hydrogen, C ⁇ galkyl, C3_7cycloalkyl, aralkyl, or together with the nitrogen atom to which they are attached form an optionally substituted 5- to 7-membered heterocyclic ring which may contain an additional heteroatom selected from oxygen, nitrogen or sulfur, where optional substituents include C ⁇ _ 6 alkyl, aryl, CONR 8 R 89 , NR 90 R 91 , hydroxy, OCOR 92 , NHCOCF3, NHSO 2 R 93 , NHCO 2 R 94 , or NHCOC 0 _6alkyl wherein the alkyl of NHCOC 0 _6alkyl is optionally substituted by OH;
- Z is an optionally substituted 5 to 7-membered heterocyclic ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen or sulfur;
- R 88 , R 89 , R 90 , R 91 , R 92 , R 95 , and R 96 are independently hydrogen or Ci _ ⁇ alkyl;
- R 93 and R 94 are independently Ci.galkyl; ac is 0 to 4; ad is 1, 2 or 3; ae is 0, 1 or 2; alternatively, E
- R 97 and R 98 are independently hydrogen, C ⁇ _6alkyl, C3_7cycloalkyl, aralkyl, or together with the nitrogen atom to which they are attached form an optionally substituted 5- to 7-membered heterocyclic ring which may contain an additional heteroatom selected from oxygen, nitrogen or sulfur, where optional substituents include C ⁇ _ 6 alkyl, aryl, CONR 102 R 103 , NR 104 R 105 , hydroxy, OCOR 106 , NHCOCF3, NHSO 2 R 107 , NHCO 2 R 108 , or NHCOC 0 _6alkyl wherein the alkyl of NHCOCo-6alkyl is optionally substituted by OH;
- R 99 and RIOO ⁇ e independently hydrogen or C ⁇ galkyl;
- AC is oxygen, CR 1 1 ⁇ R 112 or NR 113 or AC is a group SfO) ⁇ ;
- R 104 R 105, R 106, R 109, R 110, R lll, R112, and R 113 m independently hydrogen or C ⁇ _gal yl;
- R 107 and R 108 are independently Ci.galkyl; af is O, l, 2, 3, or 4; ag is 1, 2, or 3; ah is 1, 2, 3 or 4; ai is 2, 3 or 4; aj is O, 1, 2, or 3; and ak is 0, 1 or 2.
- af is O, l, 2, 3, or 4
- ag is 1, 2, or 3
- ah is 1, 2, 3 or 4
- ai 2, 3 or 4
- aj is O, 1, 2, or 3
- ak is 0, 1 or 2.
- E may be optionally quatemized with C ⁇ _ ⁇ alkyl or is optionally present as the N-oxide.
- A' is aryl or heteroaryl, each of which is optionally substituted with one or more of R*'.
- A' is suitably aryl or heteroaryl fused to a saturated or partly unsaturated 5-7-membered ring to form a higher order ring moiety, which ring moiety optionally contains 1 or 2 heteroatoms selected from oxygen, nitrogen or sulfur, wherein nitrogen may be optionally substituted with hydrogen, C ⁇ galkyl or C3_ 7cycloalkyl; wherein the higher order ring moiety is optionally substituted with one or more of R 1 '.
- A' is phenyl, 5,6,7,8-tetrahydro-l-naphthalenyl, lH-indol-4-yl, or 2-benzothiazolyl.
- Rl' is hydrogen, Cj_6alkyl, C 2 _6alkenyl, C _galkynyl, C3. 7 cycloalkyl, C 3 _6cycloalkenyl, CH 2 CF 3 , aryl, aralkyl, (CH 2 ) a 'NR 2 'R 3 ', (CH 2 ) a 'NR 2 'COR 4 ', (CH 2 ) a NR 2 CO 2 R5', (CH 2 ) a 'NR 2 SO R6', (CH ) a CONR 7 'R 8 ', hydroxyC ⁇ _6alkyl, C ⁇ alkoxy alkyl (optionally substituted by a C ⁇ _4alkoxy or hydroxy group), (CH 2 ) a CO 2 C ⁇ _ 6 alkyl, (CH 2 ) b C(O)R 9 ', CRlO ⁇ NOR 11 ', CNRiO ⁇ NORll', COR 12
- NR 18 'CONR 18 'R 19 ', NR 2 'CO 2 R 5 ', NR 2 'SO 2 R 6 ', N CNR 1 'NRl 'Rl 9 ', nitro, hydroxy, C ⁇ .galkoxy, OCF3, hydroxyC ⁇ _6a ⁇ koxy, C ⁇ _6alkoxyC ⁇ _6a ⁇ ko y, OC(O)NR 20 'R 21 ', SR 22 ', SOR 23 ', SO R 23 ', SO 2 NR 20 R 21 ' or halogen, or suitably R!
- heterocyclic ring is a 5- to 7-membered heterocyclic ring containing 1 to 4 heteroatoms selected from oxygen, nitrogen, or sulfur
- suitable heterocyclic rings include aromatic groups such as thienyl, furyl, pyrrolyl, triazolyl, diazolyl, imidazolyl, oxazolyl, thiazolyl, oxadiazolyl, isothiazolyl, isoxazolyl, thiadiazolyl, pyridyl, pyrimidyl, pyrazinyl, and dioxanyl.
- Saturated and partially saturated rings are also within the scope of the invention, in particular rings including an oxo or thioxo moiety such as lactams and thiolactams.
- the heterocyclic ring can be linked to the remainder of the molecule via a carbon atom, or, when present, a nitrogen atom.
- these rings may be optionally substituted with one or more of hydrogen, Cj.galkyl, C3_7cycloalkyl, C3., 6cycloalkenyl, CONR 7 R 8 ', CO 2 R 17 ', cyano, aryl, trifluoromethyl, nitro, hydroxy, Cj.galkoxy, acyloxy, or halogen.
- R 1 ' is one or more of C .galkyl, (CH 2 ) a NR 2 COR 4 , CF3, CO2C!.6alkyl, Cj.gaikoxy, halogen, or cyano.
- R 2 and R 3 are independently hydrogen or C ⁇ alkyl, or suitably, R 2 ' and R 3 together with the nitrogen to which they are attached, form a 5- to 6-membered heterocyclic ring.
- the ring may be optionally substituted by an oxo group, or, when R 2 ' and R 3 form a 6-membered ring, the ring may optionally contain one oxygen or one sulfur atom.
- the oxygen or sulfur atom are preferably in the 4-position.
- R 4 ' is hydrogen, or, when Rl' is
- R 5 ' is C ⁇ galkyl.
- R ⁇ ' is Ci.gal yl or phenyl.
- R 7 ' and R 8 are independently hydrogen or C ⁇ .galkyl, or suitably, R 7 and R 8 ' together with the nitrogen to which they are attached form a 5- to 6-membered saturated heterocyclic ring.
- the ring may optionally contain one oxygen or one sulfur atom.
- R 9 ' is Ci ⁇ alkyl, wherein the C ⁇ galkyl is optionally substituted by a
- R 1 ⁇ ' and R* 1 ' are independently hydrogen or C ⁇ galkyl.
- R i2 ' is hydrogen or Cj.galkyl.
- Rl ' is hydrogen or C ⁇ alkyl.
- R* 4 ' and R 1 ⁇ ' are independently hydrogen or Cj.galkyl.
- R ⁇ ' is hydrogen or C ⁇ .galkyl.
- R l7 ' is hydrogen or Ci ⁇ alkyl, wherein the C ⁇ .galkyl is optionally substituted with one or more substituents selected from Cj.galkyl, Cj.galkoxy, hydroxy, or NR 2 'R 3 .
- substituents selected from Cj.galkyl, Cj.galkoxy, hydroxy, or NR 2 'R 3 .
- there is more than one substituent there are two substituents.
- R i8 ' and R are independently hydrogen or C ⁇ alkyl.
- R 2 ⁇ ' and R 21 ' are independently hydrogen or Ci ⁇ alkyl, or suitably,
- R20' an d R 2i ' together with the nitrogen to which they are attached form a 5- to 6- membered saturated heterocyclic ring which, when there are 6 ring members, may optionally contain in the ring one oxygen or one sulfur atom.
- R 2 ' is hydrogen or C ⁇ galkyl.
- R 23 ' is Ci _6alkyl.
- D' is either a bond or represents [C(R 24 ') 2 ] a » [C(R 2 ')2] a "CO, SO 2 ,
- CR2 4 ' CR 4 'CO, C ⁇ CCO, (C(R 24 ') 2 ) c "SO 2 , SO 2 [C(R 24 ') 2 ] a ",
- D' may further be O, NR25', C0NR25', SO 2 NR 2 5', OCONR 2 5' ; NR25 COO, NR25 CO NR 5', [C(R 24 ') 2 ] a "NR 2 5 '[C(R 24 ') 2 ] b » [C(R 24 '
- D' is a bond, CO or SO 2 .
- R2 4 ' is hydrogen or C ⁇ galkyl.
- R25' is hydrogen or C ⁇ alkyl.
- E' and G' together are NC(R 26 ) 2 .
- R 2 ⁇ ' is hydrogen or Cj.galkyl.
- R 2 " is hydrogen.
- R 27 ' is hydrogen, OR 28 ', NHR 28 ', CN, NO 2 , R 28 ', SR 29 ', COR 29 ',
- R 28 is hydrogen, C ⁇ alkyl, aryl or aralkyl.
- R 29 ' is C ⁇ _5alkyl, aryl or aralkyl.
- R' is one or more of hydrogen or C ⁇ _6alkyl, or R' is oxo.
- R' is hydrogen.
- J' is CO or SO2.
- J' is CO.
- L' is NR 30 ', O, or C(R 30 ') 2 .
- L' is NR 30 '.
- R 30 ' is hydrogen or C .galkyl.
- R 30 ' is hydrogen.
- substituent E is selected from the following groups:
- E suitably represents a group (a):
- B is preferably CR 7 R 8 , or oxygen.
- R 1 and R2 are suitably independently hydrogen or Ci ⁇ alkyl.
- R 1 and R2 are each hydrogen.
- B(CRiR 2 ) a is OCR 1 R 2 CR 1 (OH)CR 1 R2 or
- B(CRlR 2 ) a is OCR 1 R 2 CR 1 (OH)CR1R 2 or OCR 1 R 2 CR 1 (OCOCH 3 )CR 1 R 2 , Rl and R 2 are hydrogen.
- R 3 and R 4 are suitably independently hydrogen, C ⁇ galkyl, C3_7cycloalkyl, aralkyl, or together with the nitrogen atom to which they are attached form an optionally substituted 5- to 7-membered heterocyclic ring which may contain an additional heteroatom selected from oxygen, nitrogen or sulfur, where optional substituents include C ⁇ galkyl, aryl, CONR ⁇ R 11 , NR ⁇ R 11 , hydroxy, OCOR 12 , NHCOCF3, NHSO 2 R 13 , NHCO 2 R 14 , or NHCOCo-6alkyl wherein the alkyl of NHCOCo_6alkyl is optionally substituted by OH.
- R 3 and R 4 are independently Ci ⁇ galkyl, C3_7cycloalkyl, or together with the nitrogen atom to which they are attached form an optionally substituted 5- to 7-membered heterocyclic ring which may contain an additional heteroatom selected from oxygen, nitrogen or sulfur.
- B-(CR!R 2 ) a -NR 3 R 4 is ortho to R 5 , meta to L' and para to R 6 , and R5 is para to L'.
- R 5 is suitably hydrogen, Ci ⁇ alkyl, aryl, CN, CONR 15 R 16 , CO2R 17 , trifluoromethyl, NHCO 2 R 18 , hydroxy, Cj ⁇ galkoxy, benzyloxy, OCH 2 CO 2 C ⁇ _6alkyl, OCF3, S(O) d R 19 , SO 2 NR 2 °R 21 , or halogen.
- R 5 is preferably SC ⁇ _ galkyl or halogen.
- R 6 is hydrogen.
- R 7 , R 8 , Rl°, RU, Rl2, R15, R16 ; R 17, R 20, R 21 ; R 22 5 an R 23 ⁇ suitably independently hydrogen or C ⁇ . ⁇ alkyl.
- R 9 is suitably hydrogen, R 13 , R l4 R 18 , and R 19 are suitably independently C ⁇ galkyl.
- a is suitably 1, 2, 3, or 4.
- b is suitably 1 or 2.
- b is 1.
- c and d are suitably independently 0, 1, or 2.
- e is suitably 2, 3, or 4.
- f is suitably 0, 1, 2, or 3.
- E suitably represents a group (b):
- R 24 , R25 5 R 26 5 R 27 ; R 28 ; R 29 ⁇ R 31 ; and R 32 ⁇ Q suitably independently hydrogen or C ⁇ alkyl.
- R 30 is suitably hydrogen, C ⁇ _galkyl, or C3_7cycloalkyl.
- R 30 is C _
- R 33 is hydrogen.
- J is suitably oxygen, CR 3o R 37 , or NR 38 , or J is a group 8(0) ⁇ .
- J is oxygen.
- J is para to L ⁇
- R 34 , R 3 ⁇ , R 3 °, R 37 , R 38 are suitably independently hydrogen or C j _galkyl.
- g is suitably 1, 2, or 3.
- h is suitably 1, 2, or 3.
- h is 1.
- i is suitably 2, 3, or 4.
- j is suitably 0, 1, 2, or 3.
- k is suitably 0, 1 or 2.
- E suitably represents a group (c):
- E suitably represents a group (f):
- R ⁇ 7 and R ⁇ 8 are independently hydrogen or Cj.galkyl; suitably R ⁇ 9 and R6° are independently hydrogen, Ci. ⁇ alkyl, C3_7cycloalkyl, aralkyl, or together with the nitrogen atom to which they are attached form an optionally substituted 5- to 7-membered heterocyclic ring which may contain an additional heteroatom selected from oxygen, nitrogen or sulfur, where optional substituents include C ⁇ galkyl, aryl, CONR 61 R 62 , NR 61 R 62 , hydroxy, OCOR6 3 , NHCOCF3, NHSO R 64 , NHCO 2 R65 or NHCOCo_6alkyl wherein the alkyl of NHCOCo_6alkyl is optionally substituted by OH, and wherein R°l, R62 ; anc ⁇ R 63 ⁇ g independently hydrogen or C j .galkyl, and R ⁇ 4 and R65 are independently Cj.galkyl; suitably, T is -
- R 71 is an optionally substituted 5- to 7-membered saturated or partially saturated heterocyclic ring containing a nitrogen atom and optionally a further one or two heteroatoms selected from nitrogen, oxygen or sulfur
- R x is an optionally substituted 6,6 or 6,5-bicyclic ring system containing a nitrogen atom and optionally a further heteroatom selected from oxygen, nitrogen or sulfur, which ring systems may be optionally substituted with one or more of C ⁇ .galkyl, and substituted on nitrogen with hydrogen, C ⁇ galkyl, or C3_7cycloalkyl.
- R 71 is an optionally substituted 5- or 6-membered saturated or partially saturated heterocyclic ring containing a nitrogen atom and substituted on nitrogen with Cj.galkyl or C3_7cycloalkyl.
- R 7 i is preferably located meta to L', ortho to R 72 and para to R 73 , and R 72 is located para to L'.
- R 72 is hydrogen, C ⁇ _ 6 alkyl, aryl, CN, CONR 74 R 75 , CO 2 R 76 , trifluoromethyl, NHCO 2 R 77 , hydroxy, C ⁇ galkoxy, benzyloxy, OCH 2 CO 2 C ⁇ _galkyl, OCF 3 , S(O) z R 78 , SO 2 NR 79 R 80 , or halogen wherein R 74 , R 75 , R 76 , R 79 and R 80 are independently hydrogen or C ⁇ alkyl, R 77 and R 78 are C ⁇ galkyl, and z is 0, 1, or 2.
- R 72 is preferably C ⁇ alkoxy, SC ⁇ galkyl or halogen.
- R 73 is hydrogen.
- y is an integer from 1-2. Preferably, y is 1.
- E suitably represents a group (h):
- R ⁇ 01 is hydrogen or C ⁇ .galkyl or R i i and R 30 ' together form a group -AD- wherein AD is (CR i09 R i l0 )ai wherein ai is 2, 3 or 4 or AD is (CR 109 R! 10 ) a j-AE wherein aj is 0, 1, 2 or 3 and AE is oxygen, sulfur or
- R 109 CR! 10
- R 109 and R 110 are independently hydrogen or C galkyl; suitably, R 97 and R 98 are independently hydrogen, C3_7cycloalkyl, aralkyl, or together with the nitrogen atom to which they are attached form an optionally substituted 5- to 7-membered heterocyclic ring which may contain an additional heteroatom selected from oxygen, nitrogen or sulfur, where optional substituents include C j .galkyl, aryl, CONR1°2R1° 3 , NR i04 R 10 5, hydroxy, OCOR 106 , NHCOCF3, NHSO 2 R 107 , NHCO 2 R 108 , or NHCOC 0 -6alkyl wherein the alkyl of NHCOC 0 _6alkyl is optionally substituted by OH, and wherein R 102 , Rl° 3 , R1° 4 R 105 and Rl°6 are independently hydrogen or C ⁇ galkyl, and R 107 and R 108 are independently
- AC is oxygen, CRI HR 1 * 2 G r NR 113 wherein R 111 , R 112 and 113 are independently hydrogen or Cj.galkyl or AC is a group S(O)ak wherein ak is 0, 1 or 2; suitably, ag is an integer from 1-3, ah is an integer from 1-4, and af is 0-4.
- A' is phenyl, 5,6,7,8-tetrahydro-l-naphthalenyl, lH-indol-4-yl, or 2- benzothiazolyl
- R 1 ' is one or more of C ⁇ galkyl, (CH 2 ) a NR 2 COR 4 CF 3 , CO 2 C ⁇ _ ⁇ alkyl, C ⁇ galkoxy, halogen, or cyano
- D' is a bond
- E' and G' together are NC(R 2 6) 2
- R' is hydrogen
- J' is CO
- L' is NR 30
- E is group (a), (b), (c), (f), (g), (h), or (i).
- A' is phenyl, 5,6,7,8-tetrahydro-l-napthalenyl, lH-indol-4-yl, or 6-chloro-2-benzothiazolyl; and when A' is phenyl, R 1 ' is one or more of Cj.galkyl, CF3, CO 2 CH 2 CH3, C ⁇ _6alkoxy, halogen, or cyano substituted at the 2,3-, 2,4-, 2,5-, 2- , 3-, 4-, 3,4-, and 3,5- positions, D' is a bond, E' and G' together are NCH 2 , R' is hydrogen, J' is CO, L' is NH, and E is a group (a), (b), or (g). Preferably, E is selected from group (a), (b) and (g).
- E is group (a)
- L' is attached to group (a) meta to B- (CR 1 R 2 ) a -NR 3 R 4 and para to (R 5 ) b , wherein B is oxygen or CR 7 R 8 , R!
- R 2 are hydrogen, R ⁇ is methoxy, methylthio or iodo, R 3 and R 4 are independently C3_6alkyl, or R 3 and R 4 taken together with the nitrogen to which they are attached form a 5- or 6- membered heterocyclic ring optionally substituted with one or more of Cj.galkyl and acetamido or hydroxyl, R" is hydrogen, a is 2 or 3 when B is oxygen and a is 2 when B is CR 7 R 8 , and b is l.
- L' is attached to group (a) meta to B- (CR!R 2 ) a -NR 3 R 4 and para to (R 5 ) b , wherein B is oxygen or CH2, R 1 and R 2 are hydrogen, R ⁇ is methoxy, R 3 and R 4 are independently isopropyl or tert-butyl, or R 3 and R 4 taken together with the nitrogen to which they are attached are 1 -(2,2,6,6- tetramethylpiperidinyl), l-(4-acetamido-2,2,6,6-tetramethyl piperidinyl), l-(4-hydroxy- 2,2,6,6-tetramethyl piperidinyl) or l-(4-hydroxy-2,2,4,6,6-pentamethyl piperidinyl), R ⁇ is hydrogen, a is 2 when B is oxygen, and b is 1.
- E is group (b)
- L' is attached to group (b) para to J
- J is oxygen
- R 33 is hydrogen
- R 24 R 25 , R 26 , R 27 , R 28 , R 29 , R 31 and R 32 are hydrogen
- R 30 is C3_6alkyl
- g is 2 and h is 1.
- E is group (b)
- L' is attached to group (b) para to J
- J is oxygen
- R 33 is hydrogen
- R 24 , R 25 , R 26 , R 27 , R 28 , R 29 , R 31 and R 32 are hydrogen
- R 30 is isopropyl
- g is 2
- h is 1.
- R x is an optionally substituted 5- or 6-membered saturated or partially saturated heterocyclic ring containing a nitrogen atom substituted on nitrogen with C3_galkyl or C3_7cycloalkyl, R 72 is methoxy, methylthio or iodo, y is 1, and R 73 is hydrogen.
- L' is attached to group (g) meta to R 7 * and para to R 72 wherein R 7i is piperidin-4-yl substituted on nitrogen with isopropyl, R 72 is methoxy, y is 1, and R 73 is hydrogen.
- a particularly effective subgenus of compounds of formula (I) is wherein, A' is phenyl, 5,6,7,8-tetrahydro-l-naphthalenyl, or lH-indol-4-yl; and when A' is phenyl, R 1 ' is methyl, chloro or trifluoromethyl substituted at the 2 and/or 3-positions, or R 1 ' is 2,4- dimethyl, 2-methoxy-5-chloro, 2-methyl, 3-ethoxycarbonyl, or 3,5-dichloro, D' is a bond, E' and G' together are NCH2, R' is hydrogen, J' is CO, L' is NH, and E is group
- acyloxy is used herein at all occurrences to mean a moiety
- alkenyl is used herein at all occurrences to mean a straight or branched chain radical of 2 to 6 carbon atoms, unless the length is limited thereto, wherein there is at least one double bond between two of the carbon atoms in the chain, including, but not limited to, ethenyl, 1-propenyl, 2-propenyl, 2-methyl-l-propenyl, 1- butenyl, 2-butenyl, and the like.
- alkoxy is used herein at all occurrences to mean a straight or branched chain radical of 1 to 6 carbon atoms, unless the chain length is limited thereto, bonded to an oxygen atom, including, but not limited to, methoxy, ethoxy, n- propoxy, isopropoxy, and the like.
- C ⁇ _5alkoxyC ⁇ _6alkoxy is used herein at all occurrences to mean an alkoxy group as defined above, substituted with an alkoxy group as defined above.
- C]i _6a ⁇ kyl is used herein at all occurrences to mean a straight or branched chain radical of 1 to 6 carbon atoms, unless the chain length is limited thereto, including, but not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, and the like.
- alkynyl is used herein at all occurrences to mean a straight or branched chain radical of 2 to 8 carbon atoms, unless the chain length is U ited thereto, wherein there is at least one triple bond between two of the carbon atoms in the chain, including, but not limited to, acetylene, 1- propylene, 2-propylene, and the like.
- aralkyl is used herein at all occurrences to mean an aryl moiety as defined above, which is connected to an alkyl moiety as defined below including, but not limited to, benzyl or phenethyl, and the like.
- aryl is used herein at all occurrences to mean a 6-14-membered substituted or unsubstituted aromatic ring(s) or ring systems which may include bi- or tri-cyclic systems, including, but not limited to, phenyl, naphthalenyl, biphenyl, phenanthryl, anthracenyl, and the like.
- 6,6 or 6,5 bicyclic ring is used herein at all occurrences to mean a 6,6 or 6,5-bicyclic ring system containing a nitrogen atom and optionally a further heteroatom selected from nitrogen, oxygen, or sulfur, which ring system may be optionally substituted with C]i _5alkyl.
- ring systems include, but are not limited to, tropane, isoquinuclidine and granatane rings.
- cycloalkenyl is used herein at all occurrences to mean cyclic radicals, preferably of 5 to 8 carbons, which have at least one double bond between two of the carbon atoms in the ring, including but not limited to, cyclopentenyl, cyclohexenyl, and the like.
- cycloalkyl and “cyclic alkyl” are used herein at all occurrences to mean cyclic radicals, preferably comprising 3 to 7 carbon atoms which may be mono- or bicyclo- fused ring systems which may additionally include unsaturation, including, but not limited to, cyclopropyl, cyclopentyl, cyclohexyl, 1,2,3,4- tetrahydronaphthalenyl, and the like.
- halo or halogen are used interchangeably herein at all occurrences to mean radicals derived from the elements chlorine, fluorine, iodine and bromine.
- heteroaryl is used herein at all occurrences to mean a 5-14- membered substituted or unsubstituted aromatic ring(s) or ring systems which may include bi- or tri-cyclic systems, which ring or ring systems contain 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulfur, including, but not limited to, indolyl, benzofuranyl, thianaphthenyl, quinolyl, isoquinolyl, pyrrolyl, furanyl, thienyl, pyridyl, and the like.
- hydroxyCi.galkoxy is used herein at all occurrences to mean an hydroxyl group bonded to an alkoxy group as defined above including, but not limited to, -O-CH 2 -CH(OH)CH 3 and the like.
- hydroxyalkyl are used herein interchangeably to mean an hydroxyl group bonded to a C ⁇ _6alkyl group as defined above, including, but not limited to, methanol, ethanol, n-propanol, isopropanol, n- butanol, sec-butanol, isobutanol, tert-butanol, and the like.
- heterocyclic ring is used herein at all occurrences to mean a saturated or partially saturated 5-10-membered ring system (unless the cyclic ring system is otherwise limited) in which the ring system contains one to 3 heteroatoms selected from oxygen, sulfur, or nitrogen, which ring system may be optionally substituted with Cj.galkyl.
- examples of such rings include, but are not limited to, piperidine, tetrahydropyridine, piperazine, pyrrolidine, morpholine, imidazolidine, pyrazolidine, hexahydroazepine, and the like.
- heterocyclic ring When the heterocyclic ring is fused to a phenyl group, as when E is the group (h), the term "heterocyclic ring", together with the phenyl ring to which it is fused, forms a ring which includes, but is not limited to, dihydro- 1,4-benzoxazine and 1,2,3,4-tetrahydroquinoline, which may be optionally substituted by C ⁇ gal yl or oxo.
- heteroatom is used herein at all occurrences to mean an oxygen atom, a sulfur atom or a nitrogen atom. It will be recognized that when the heteroatom is nitrogen, it may form an NR a or NR a R b moiety, wherein R a and R b are, independently, hydrogen or C 1 to Cg alkyl, or together with the nitrogen to which they are bound, form a saturated or unsaturated 5-, 6- or 7-membered ring, including, but not limited to, pyrrolidine, piperidine, piperazine, morpholine, pyridine, and the like.
- the saturated or unsaturated 5-, 6- or 7-membered ring may optionally have one or more additional heteroatoms in the ring.
- optionally substituted is used herein at all occurrences to mean an optionally substituted 5- to 7-membered heterocyclic ring wherein the optional substituents are one or more of C ⁇ galkyl.
- CCR5 mediated disease state is used herein at all occurrences to mean any disease state which is mediated (or modulated) by CCR5.
- pharmaceutically acceptable salts of formula (I) include, but are not limited to, salts with inorganic acids such as hydrochloride, sulfate, phosphate, diphosphate, hydrobromide, and nitrate, or salts with an organic acid such as malate, maleate, fumarate, tartrate, succinate, citrate, acetate, lactate, methanesulfonate, p- toluenesulfonate, palmitate, salicylate, and stearate.
- inorganic acids such as hydrochloride, sulfate, phosphate, diphosphate, hydrobromide, and nitrate
- an organic acid such as malate, maleate, fumarate, tartrate, succinate, citrate, acetate, lactate, methanesulfonate, p- toluenesulfonate, palmitate, salicylate, and stearate.
- the compounds of the invention can exist in unsolvated as well as solvated forms, including hydrated forms.
- solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like, are equivalent to the unsolvated forms for purposes of this invention.
- the compounds of the present invention may contain one or more asymmetric carbon atoms and may exist in racemic and optically active forms.
- the stereocenters may be of any combination of R and S configuration, for example, (R,R), (R,S), (S,S) or (S,R). All of these compounds are within the scope of the present invention.
- the preferred compounds of the invention are the following compounds:
- the pharmaceutically effective compounds of this invention are administered in conventional dosage forms prepared by combining a compound of formula (I) ("active ingredient”) in an amount sufficient to treat COPD, asthma and atopic disorders (for example, atopic dermatitis and allergies), rheumatoid arthritis, sarcoidosis, or idiopathic pulmonary fibrosis and other fibrotic diseases, atherosclerosis, psoriasis, autoimmune diseases such as multiple sclerosis, treating and/or preventing rejection of transplanted organs, inflammatory bowel disease, and HIV infection, ("CCR5-mediated disease states”) with standard pharmaceutical carriers or diluents according to conventional procedures well known in the art. These procedures may involve mixing, granulating and compressing or dissolving the ingredients as appropriate to the desired preparation.
- the pharmaceutical carrier employed may be, for example, either a solid or liquid.
- solid carriers are lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid and the like.
- liquid carriers are syrup, peanut oil, olive oil, water and the like.
- the carrier or diluent may include time delay material well known to the art, such as glyceryl monostearate or glyceryl distearate alone or with a wax.
- the preparation can be tableted, placed in a hard gelatin capsule in powder or pellet form or in the form of a troche or lozenge.
- the amount of solid carrier will vary widely but preferably will be from about 25 mg to about 1000 mg.
- the preparation will be in the form of a syrup, emulsion, soft gelatin capsule, sterile injectable liquid such as an ampule or nonaqueous liquid suspension.
- the active ingredient may also be administered topically to a mammal in need of treatment or prophylaxis of CCR5 mediated disease states.
- the amount of active ingredient required for therapeutic effect on topical administration will, of course, vary with the compound chosen, the nature and severity of the disease state being treated and the mammal undergoing treatment, and is ultimately at the discretion of the physician.
- a suitable dose of an active ingredient is 1.5 mg to 500 mg for topical administration, the most preferred dosage being 1 mg to 100 mg, for example 5 to 25 mg administered two or three times daily.
- topical administration non-systemic administration and includes the application of the active ingredient externally to the epidermis, to the buccal cavity and instillation of such a compound into the ear, eye and nose, and where the compound does not significantly enter the blood stream.
- systemic administration is meant oral, intravenous, intraperitoneal and intramuscular administration.
- an active ingredient may be administered alone as the raw chemical, it is preferable to present it as a pharmaceutical formulation.
- the active ingredient may comprise, for topical administration, from 0.001% to 10% w/w, e.g. from 1% to 2% by weight of the formulation although it may comprise as much as 10% w/w but preferably not in excess of 5% w/w and more preferably from 0.1% to 1% w/w of the formulation.
- topical formulations of the present invention comprise an active ingredient together with one or more acceptable carrier(s) therefor and optionally any other therapeutic ingredient(s).
- the carrier(s) must be 'acceptable' in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
- Formulations suitable for topical administration include liquid or semi-liquid preparations suitable for penetration through the skin to the site of inflammation such as liniments, lotions, creams, ointments or pastes, and drops suitable for administration to the eye, ear or nose.
- Drops according to the present invention may comprise sterile aqueous or oily solutions or suspensions and may be prepared by dissolving the active ingredient in a suitable aqueous or alcoholic solution of a bactericidal and/or fungicidal agent and/or any other suitable preservative, and preferably including a surface active agent.
- the resulting solution may then be clarified by filtration, transferred to a suitable container which is then sealed and sterilized by autoclaving or maintaining at 98-100°C for half an hour.
- the solution may be sterilized by filtration and transferred to the container by an aseptic technique.
- bactericidal and fungicidal agents suitable for inclusion in the drops are phenylmercuric nitrate or acetate (0.002%), benzalkonium chloride (0.01%) and chlorhexidine acetate (0.01%).
- Suitable solvents for the preparation of an oily solution include glycerol, diluted alcohol and propylene glycol.
- Lotions according to the present invention include those suitable for application to the skin or eye.
- An eye lotion may comprise a sterile aqueous solution optionally containing a bactericide and may be prepared by methods similar to those for the preparation of drops.
- Lotions or liniments for application to the skin may also include an agent to hasten drying and to cool the skin, such as an alcohol or acetone, and/or a moisturizer such as glycerol or an oil such as castor oil or arachis oil.
- Creams, ointments or pastes according to the present invention are semi-solid formulations of the active ingredient for external application. They may be made by mixing the active ingredient in finely-divided or powdered form, alone or in solution or suspension in an aqueous or non-aqueous fluid, with the aid of suitable machinery, with a greasy or non-greasy basis.
- the basis may comprise hydrocarbons such as hard, soft or liquid paraffin, glycerol, beeswax, a metallic soap; a mucilage; an oil of natural origin such as almond, corn, arachis, castor or olive oil; wool fat or its derivatives, or a fatty acid such as stearic or oleic acid together with an alcohol such as propylene glycol.
- the formulation may incorporate any suitable surface active agent such as an anionic, cationic or non-ionic surfactant such as esters or polyoxyethylene derivatives thereof.
- suitable surface active agent such as an anionic, cationic or non-ionic surfactant such as esters or polyoxyethylene derivatives thereof.
- Suspending agents such as natural gums, cellulose derivatives or inorganic materials such as silicaceous silicas, and other ingredients such as lanolin, may also be included.
- the active ingredient may also be administered by inhalation.
- inhalation is meant intranasal and oral inhalation administration.
- Appropriate dosage forms for such administration such as an aerosol formulation or a metered dose inhaler, may be prepared by conventional techniques.
- the daily dosage amount of the active ingredient administered by. inhalation is from about 0.1 mg to about 100 mg per day, preferably about 1 mg to about 10 mg per day.
- this invention relates to a method of treating COPD, asthma and atopic disorders (for example, atopic dermatitis and allergies), rheumatoid arthritis, sarcoidosis, or idiopathic pulmonary fibrosis and other fibrotic diseases, atherosclerosis, psoriasis, autoimmune diseases such as multiple sclerosis, treating and/or preventing rejection of transplanted organs, inflammatory bowel disease, and HIV infection, all in mammals, preferably humans, which comprises administering to such mammal an effective amount of a CCR5 receptor modulator, in particular, a compound as depicted in formula (I).
- atopic disorders for example, atopic dermatitis and allergies
- sarcoidosis for example, atopic dermatitis and allergies
- idiopathic pulmonary fibrosis and other fibrotic diseases for example, atherosclerosis, psoriasis, autoimmune diseases such as multiple sclerosis
- autoimmune diseases such as multiple sclerosis
- formula (I) compound can be administered to such mammal in a conventional dosage form prepared by combining the formula (I) compound with a conventional pharmaceutically acceptable carrier or diluent according to known techniques. It will be recognized by one of skill in the art that the form and character of the pharmaceutically acceptable carrier or diluent is dictated by the amount of active ingredient with which it is to be combined, the route of administration and other well- known variables.
- the formula (I) compound is administered to a mammal in need of treatment for COPD, asthma and atopic disorders (for example, atopic dermatitis and allergies), rheumatoid arthritis, sarcoidosis, or idiopathic pulmonary fibrosis and other fibrotic diseases, atherosclerosis, psoriasis, autoimmune diseases such as multiple sclerosis, treating and/or preventing rejection of transplanted organs, inflammatory bowel disease, and HIV infection, in an amount sufficient to decrease symptoms associated with these disease states.
- the route of administration may be oral or parenteral.
- the invention relates to a method for modulating factors which exacerbate the symptoms of the CCR5-mediated diseases described herein.
- parenteral as used herein includes intravenous, intramuscular, subcutaneous, intra-rectal, intravaginal or intraperitoneal administration.
- the subcutaneous and intramuscular forms of parenteral administration are generally preferred.
- the daily parenteral dosage regimen will preferably be from about 30 mg to about 300 mg per day of active ingredient.
- the daily oral dosage regimen will preferably be from about 100 mg to about 2000 mg per day of active ingredient. It will be recognized by one of skill in the art that the optimal quantity and spacing of individual dosages of a formula (I) compound will be determined by the nature and extent of the condition being treated, the form, route and site of administration, and the particular mammal being treated, and that such optimums can be determined by conventional techniques.
- the compounds of formula (I) can be prepared by art-recognized procedures from known or commercially available starting materials. If the starting materials are unavailable from a commercial source, their synthesis is described herein, or they can be prepared by procedures known in the art.
- compounds of formula (I) where L' is NR 30 are prepared by treating a suitably substituted aniline 1-1 with suitable reagent, for example triphosgene, and a suitable base, for example triethylamine, in a suitable solvent, for example dichloromethane, followed by treatment with a suitably substituted amine 1-2, e.g., l-(5,6,7,8-tetrahydro-l-naphthalenyl)piperazine, ethyl 3-(l-piperazinyl)benzoate, 4- (phenyl)piperidine, l-(phenyl)piperazine, 4-phenyl-2,3,4,6-tetrahydropyrdine, hexahydro- l-phenyl-lH-l,4-diazepine, etc., to afford the title compound 1-3.
- suitable reagent for example triphosgene
- a suitable base for example triethylamine
- a suitable solvent for example dichlor
- Suitably substituted anilines used to prepare compounds of formula (I) where E is a group of formula (b) are prepared according to the methods of international application publication number WO 95/11934, published 25 April 1995, and WO 95/19477, published 27 June 1995.
- Four other applications relate to the spiro compounds WO 97/17350 published 15 May 1997; WO 97/34900 published 25 September 1997; WO 97/34901 published 25 September 1997; WO 97/35862 published 2 October 1997.
- Suitably substituted anilines used to prepare compounds of formula (I) where E is a group of formula (c) are prepared according to the methods of international application publication number WO 95/30675, published 16 November 1995.
- Suitably substituted anilines used to prepare compounds of formula (I) where E is a group of formula (f) are prepared according to the methods of international application publication number WO 95/17401, published 29 June 1995.
- Suitably substituted anilines used to prepare compounds of formula (I) where E is a group of formula (h) are prepared according to the methods of international application publication number WO 95/32967, published 7 December 1995 and WO 97/07120, published 27 February 1997, WO 97/07120, published 27 February 1997.
- Suitably substituted anilines used to prepare compounds of formula (I) where E is a group of formula (i) are prepared according to the methods of international application publication number WO 97/19070 published 29 May 1997.
- Nitration of the resulting N-acylated phenylpiperidine with a suitable nitrating agent for example 70% nitric acid in acetic anhydride, at a suitable temperature, for example 0°C, for a suitable time, for example 30 minutes, yields 2-2.
- a suitable reagent for example potassium carbonate
- a suitable solvent for example aqueous methanol
- R is H with a suitable alkylating agent RX where R is C ⁇ galkyl or C3_7cycloalkyl, for example isopropyl, and X is a suitable leaving group, for example iodo, bromo, methanesulfonyloxy, trifluoromefhysulfonyloxy, etc., and with a suitable base, for example potassium carbonate, in a suitable solvent, for example dimethylformamide and acetonitrile, at a suitable temperature, for example 70°C, for a suitable time, for example 20 hours gives 2-3 where R is C ⁇ _galkyl or C3_7cycloalkyl.
- RX is a suitable alkylating agent
- RX is C ⁇ galkyl or C3_7cycloalkyl, for example isopropyl
- X is a suitable leaving group, for example iodo, bromo, methanesulfonyloxy, trifluoromefhysulf
- 2-3 where R is H may be reductively alkylated on the piperidine nitrogen by treatment with a C _galdehyde, C3. gketone, or a C3_7cyclic ketone, for example, cyclopentanone, and a suitable reducing agent, for example sodium cyanoborohydride, in a suitable solvent, for example, acetic acid and methanol, for a suitable time, for example 16 hours, to afford 2-3 where R is Cx.galkyl or C3_7cycloalkyl.
- a suitable solvent for example, acetic acid and methanol
- Particularly useful intermediates for preparing compounds of formula (I) are: 4-methoxy-3 - [ 1 -( 1 -methylethyl)-4-piperidinyl]benzenamine; 4-methoxy-3 - [ 1 -cyclopentyl-4-piperidinyl]benzenamine; and 4-methoxy-3-[l-(3-pentyl)-4-piperidinyl]benzenamine.
- the invention will now be described by reference to the following examples which are merely illustrative and are not to be construed as a limitation of the scope of the present invention. In the Examples, mass spectra were performed upon a VG Zab mass spectrometer using fast atom bombardment, unless otherwise indicated.
- the mixture was maintained at 0°C for an additional 30 rnin, combined with an identical concurrently run reaction, and poured into water (600 mL).
- the pH of the resultant mixture was adjusted to >9 by the addition of aqueous sodium carbonate followed by 10% sodium hydroxide.
- the resulting mixture was extracted with dichloromethane (2 x 400 mL) and the combined organic layers were washed with brine, dried (MgSO4), and concentrated in vacuo to give 12 g (>100%) of a 2.2: 1 mixture of the title compound and its 3-nitro isomer.
- the crude product was recrystallized from methanol (30 mL) to give 5.9 g (54%) of the title compound as off-white crystals.
- Triphosgene (74 mg, 0.25 mmol) was added to a solution of 3-(2- diisopropylamino)ethoxy-4-methoxyaniline (WO 95/15954)(200 mg, 0.75 mmol) and dichloromethane (3 mL) and maintained at RT for 30 rnin.
- Triethylamine (0.30 g, 0.42 mL, 3.0 mmol) was added and the resulting mixture was stirred for 1 h, treated with l-(2,3-dimethylphenyl)piperazine (0.11 g, 0.60 mmol), and the mixture stirred at RT for 16 h. The mixture was washed with water, dried (MgSO4) and concentrated in vacuo.
- Examples 3-22 Following the procedure of Example 2, except substituting 1-phenylpiperazine, l-(2-methylphenyl)piperazine, l-[2-(acetamidomethyl)phenyl]-piperazine(GB 2309458), l-[3-(trifluoromethyl)phenyl]piperazine, l-(2-methoxyphenyl)piperazine, 1- (2-chlorophenyl)piperazine, l-(3-chlorophenyl)piperazine, l-(4- chlorophenyl)piperazine, l-(2,6-dimethylphenyl)piperazine, l-(2,3- dichlorophenyl)piperazine, and l-(3,4-dichlorophenyl)piperazine for l-(2,3- dimethylphenyl)piperazine, gave the following compounds:
- Examples 25-46 Following the procedure of Example 2, except substituting l-(3- methyipheny piperazine, l-(4-methylphenyl)piperazine, l-(2,5- dimethylphenyl)piperazine, 1 -(3 ,4-dimethylphenyl)piperazine, 1 -(3 ,5- dichlorophenyl)piperazine, l-(3-methoxyphenyl)piperazine, l-(3,5- dimethoxyphenyl)piperazine, l-[3-(ethoxycarbonyl)phenyl]piperazine, l-(2- cyanophenyl)piperazine, l-(4-cyanophenyl)piperazine, l-(2-pyridinyl)piperazine, l-(4- pyridinyl)piperazine, l-[4-chloro-3-(trifluoromethyl)phenyl]piperazine, l-[2-
- Triphosgene (12.2 mg, 0.041 mmol) was added to a solution of the compound of Preparation 1(e) (31 mg, 0.125 mmol) in dichloromethane (1 mL). The mixture was , Pj stirred for 30 rnin and then triethylamine ( 0.07 mL, 0.5 mmol) was added. The mixture was stirred an additional 1 h, treated with l-(2,3-dimethylphenyl)piperazine (31.0 mg, 0.125 mmol), and the mixture stirred at RT overnight.
- Example 48 Preparation of 4-(2.3-Dichlorophenyl)-N-r4-methoxy-3-ri-(l-methylethy -4- piperidinyllphenyl1-l-pi ⁇ erazinecarboxamide Following the procedure of Example 47, except substituting l-(2,3- dichlorophenyl)piperazine for l-(2,3-dimethylphenyl)piperazine, gave the title compound. MS(ES) m/e 505.4 [M+H]+.
- Example 49 Preparation of N-[3-(2-Diisopropylamino)ethoxy-4-methoxyphenyn-4-(3- carboxyphenyDpiperazine- 1 -carboxamide To a flask containing the compound of Example 32 (5.5 mg, 0.01 mmol) was added 0.5 ml ethanol and 0.3 N sodium hydroxide (0.1 ml, 0.03 mmol.). The mixture was stirred at RT overnight.
- Example 97 Preparation of 4-r3-(Ethoxycarbonyl)phenyll-N-r3-r3-rbis(l- methylethyl amino1propoxy1-4-methoxyphenyl1-l-piperazinecarboxamide Following the procedure of Example 2, except substituting 3-(3- diisopropylamino)propoxy-4-methoxy aniline (WO 99/01127) for 3-(2- diisopropylamino)ethoxy-4-methoxyaniline and substituting the compound of Preparation 3 for l-(2,3-dimethylphenyl)piperazine, gave the title compound. MS(ES) m/e 541.4 [M+H]+.
- Example 98-99 Preparation of 4-(2.3-Dimethylphenyl -N-[4-methoxy-3-[l-cvclopentyl-4- piperidinyl]phenyl]-l-piperazinecarboxamide and 4-(2.3-Dimethylphenyl)-N-ri-(3- pentyl)-4-methoxy-3-[l-cvclopentyl-4-piperidinyl1phenyl1-l-piperazinecarboxamide
- Example 47 except substituting the compounds of Preparation 4(b) and Preparation 5 for the compound of Preparation 1(e), gives the title compounds.
- CHO cell membranes (0.25 xlO 6 cell equivalents) derived from CHO cells stably transfected with CCR5 were incubated with 0.3 125 I-RANTES in a 96 well plate for 45 min. at room temperature (final reaction volume 200 uL). The reaction was terminated by filtration and the filters (GF/C) were washed twelve times with a solution of phosphate buffered saline containing 0.1 % bovine serum albumin and 0.05 % NaN3. The radioactivity bound to filters was measured by liquid scintillation spectrometry. Non-specific binding was determined in the presence of unlabelled RANTES (10 or 30 nM) and averages 30-50% of total binding.
- the cellular functional assay used to assess antagonist activity of compounds was RANTES-induced Ca 2+ mobilization in RBL 2H3 cells stably expressing the hCCR5 receptor (RBL 2H3 hCCR5).
- Agonist activity is determined by Ca 2+ mobilization in the same cells which is inhibitable by a selective CCR5 antagonist.
- Cells were grown to 80-100% confluency in T-150 flasks and washed with phosphate-buffered saline. Cells were lifted from the flasks by treating with 3 mL of 1 mM EDTA for 3 min.
- the percent of maximal RANTES -induced Ca + was determined for each concentration of antagonist and the IC5Q ; defined as the concentration of test compound that inhibits 50% of the maximal 33 nM RANTES response, obtained from the concentration-response curves (5-7 concentrations of antagonists).
- the compounds of this invention show CCR5 receptor modulator activity having IC50 values in the range of 0.0001 to 100 ⁇ M.
- the full structure/activity relationship has not yet been established for the compounds of this invention.
- one of ordinary skill in the art can utilize the present assays in order to determine which compounds of formula (I) are modulators of the CCR5 receptor and which bind thereto with an IC50 value in the range of 0.0001 to 100 ⁇ M.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21850500P | 2000-07-15 | 2000-07-15 | |
US218509P | 2000-07-15 | ||
PCT/US2001/022529 WO2002005819A1 (en) | 2000-07-15 | 2001-07-13 | Compounds and methods |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1313477A1 true EP1313477A1 (en) | 2003-05-28 |
EP1313477A4 EP1313477A4 (en) | 2004-03-03 |
Family
ID=22815411
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP01958995A Withdrawn EP1313477A4 (en) | 2000-07-15 | 2001-07-13 | Compounds and methods |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1313477A4 (en) |
AU (1) | AU2001280599A1 (en) |
WO (1) | WO2002005819A1 (en) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9904723D0 (en) * | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission II |
SE9904724D0 (en) | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission I |
USRE46117E1 (en) | 1999-12-22 | 2016-08-23 | Teva Pharmaceuticals International Gmbh | Modulators of dopamine neurotransmission |
KR20030024799A (en) | 2000-07-20 | 2003-03-26 | 뉴로젠 코포레이션 | Capsaicin receptor ligands |
DK1472225T3 (en) | 2002-02-01 | 2010-08-09 | Euro Celtique Sa | 2-Piperazine pyridines useful for the treatment of pain |
WO2003090748A1 (en) * | 2002-04-24 | 2003-11-06 | Takeda Pharmaceutical Compay Limited. | Use of compounds having ccr antagonism |
PT1522314E (en) * | 2002-06-26 | 2014-06-05 | Ono Pharmaceutical Co | Remedies for diseases caused by vascular contraction or dilation |
IL165862A0 (en) | 2002-06-28 | 2006-01-15 | Euro Celtique Sa | Therapeutic piperazine derivatives useful for tre ating pain |
US7262194B2 (en) | 2002-07-26 | 2007-08-28 | Euro-Celtique S.A. | Therapeutic agents useful for treating pain |
WO2004010942A2 (en) * | 2002-07-31 | 2004-02-05 | Smithkline Beecham Corporation | Substituted heterocyclic compounds as modulators of the ccr5 receptor |
US7157462B2 (en) | 2002-09-24 | 2007-01-02 | Euro-Celtique S.A. | Therapeutic agents useful for treating pain |
ATE410426T1 (en) * | 2002-12-13 | 2008-10-15 | Smithkline Beecham Corp | HETEROCYCLIC COMPOUNDS ALSCCR5 ANTAGONISTS |
JPWO2004092136A1 (en) * | 2003-04-18 | 2006-07-06 | 小野薬品工業株式会社 | Nitrogen-containing heterocyclic compounds and uses thereof |
CA2533515C (en) | 2003-07-24 | 2011-05-31 | Euro-Celtique S.A. | Heteroaryl-tetrahydropyridyl compounds useful for treating or preventing pain |
MXPA06013941A (en) | 2004-06-08 | 2007-12-10 | Neurosearch Sweden Ab | New disubstituted phenylpiperidines as modulators of dopamine and serotonin neurotransmission. |
DK1773772T3 (en) * | 2004-06-08 | 2010-09-13 | Nsab Af Neurosearch Sweden Ab | Novel disubstituted phenylpiperidines / piperazines as modulators of dopamine neurotransmission |
RU2366654C2 (en) * | 2004-06-08 | 2009-09-10 | ЭнЭсЭйБи, ФИЛИАЛ АФ НЕУРОСЕРЧ СВИДЕН АБ, СВЕРИЙЕ | New disubstituted phenyl piperidines/piperazines as modulators of dopamine neurotransmission |
US7851629B2 (en) | 2004-06-08 | 2010-12-14 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Disubstituted phenylpiperidines as modulators of dopamine and serotonin neurotransmission |
NZ555094A (en) | 2004-10-13 | 2009-07-31 | Nsab Af Neurosearch Sweden Ab | Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-n-propyl-piperidine |
EP1923388A4 (en) | 2005-08-12 | 2011-03-09 | Takeda Pharmaceutical | BRAIN / NERVE CELL PROTECTION AND THERAPEUTIC FOR SLEEP DISORDERS |
SE529246C2 (en) | 2005-10-13 | 2007-06-12 | Neurosearch Sweden Ab | New disubstituted phenyl-piperidines as modulators of dopamine neurotransmission |
JP5951625B2 (en) | 2010-11-24 | 2016-07-13 | ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨークThe Trustees Of Columbia University In The City Of New York | Non-retinoid RBP4 antagonists for the treatment of age-related macular degeneration and Stargardt disease |
MX347209B (en) | 2011-12-08 | 2017-04-19 | Teva Pharmaceuticals Int Gmbh | The hydrobromide salt of pridopidine. |
HK1206297A1 (en) | 2012-04-04 | 2016-01-08 | Teva Pharmaceuticals International Gmbh | Pharmaceutical compositions for combination therapy |
WO2013166037A1 (en) | 2012-05-01 | 2013-11-07 | The Trustees Of Columbia University In The City Of New York | Non-retinoid antagonists for treatment of eye disorders |
WO2014151936A1 (en) | 2013-03-14 | 2014-09-25 | The Trustees Of Columbia University In The City Of New York | Octahydropyrrolopyrroles, their preparation and use |
ES2700541T3 (en) | 2013-03-14 | 2019-02-18 | Univ Columbia | Octahidrociclopentapirroles, its preparation and use |
WO2014151959A1 (en) | 2013-03-14 | 2014-09-25 | The Trustees Of Columbia University In The City Of New York | N-alkyl-2-phenoxyethanamines, their preparation and use |
WO2014152013A1 (en) | 2013-03-14 | 2014-09-25 | The Trustees Of Columbia University In The City Of New York | 4-phenylpiperidines, their preparation and use |
WO2015168286A1 (en) | 2014-04-30 | 2015-11-05 | The Trustees Of Columbia University In The City Of New York | Substituted 4-phenylpiperidines, their preparaiton and use |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2722788B1 (en) * | 1994-07-20 | 1996-10-04 | Pf Medicament | NOVEL PIPERAZIDES DERIVED FROM ARYL PIPERAZINE, PROCESSES FOR THEIR PREPARATION, THEIR USE AS MEDICAMENTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME |
AR013669A1 (en) * | 1997-10-07 | 2001-01-10 | Smithkline Beecham Corp | COMPOUNDS AND METHODS |
WO2000042852A1 (en) * | 1999-01-25 | 2000-07-27 | Smithkline Beecham Corporation | Compounds and methods |
-
2001
- 2001-07-13 EP EP01958995A patent/EP1313477A4/en not_active Withdrawn
- 2001-07-13 WO PCT/US2001/022529 patent/WO2002005819A1/en not_active Application Discontinuation
- 2001-07-13 AU AU2001280599A patent/AU2001280599A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1313477A4 (en) | 2004-03-03 |
AU2001280599A1 (en) | 2002-01-30 |
WO2002005819A1 (en) | 2002-01-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1313477A1 (en) | Compounds and methods | |
WO2004011427A2 (en) | Substituted benzanilides as modulators of the ccr5 receptor | |
WO2000006146A1 (en) | Substituted anilide compounds and methods | |
WO2004010943A2 (en) | Substituted benzanilides as modulators of the ccr5 receptor | |
EP1146790A1 (en) | Compounds and methods | |
US8119627B2 (en) | Heterocyclic compounds as inhibitors of 17beta-HSD3 | |
EP1100495A1 (en) | Propenamides as ccr5 modulators | |
US6399656B1 (en) | Compounds and methods | |
EP1045693B1 (en) | Aminophenoxyacetic acid derivatives as neuroprotectants | |
WO2004010942A2 (en) | Substituted heterocyclic compounds as modulators of the ccr5 receptor | |
HUP0301187A2 (en) | Novel benzyl-piperidine-derivatives, process for their preparation and pharmaceutical compositions containing them | |
EP1870405A1 (en) | Carbonylated (Aza)cyclohexanes as dopamine D3 receptor ligands | |
EP1037635A1 (en) | Compounds and methods | |
AU2004243511A1 (en) | 3-aminomethyl-pyrrolidines as N-type calcium channel blockers | |
JPH07509219A (en) | 4-[4'-piperidinyl or 3'-pyrrolidinyl]-substituted imidazoles as H↓3 receptor antagonists and methods of therapeutic use thereof | |
AU2006214118B2 (en) | Kappa opioid receptor ligands | |
JP2013028538A (en) | Novel amide derivative | |
WO2001064213A1 (en) | Compounds and methods | |
JPWO2004052859A1 (en) | Erythropoietin production promoter | |
EP1140072A1 (en) | Compounds and methods | |
TW201006799A (en) | Novel compounds active as muscarinic receptor antagonists | |
JP4276070B2 (en) | Cyclic amine compound | |
CA2515516A1 (en) | Carboxylic acid compounds | |
US20040038982A1 (en) | Compounds and methods | |
JP4451060B2 (en) | Substituted heterocyclic compounds for treating multidrug resistance |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20030210 |
|
AK | Designated contracting states |
Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20040119 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: 7C 07D 211/26 B Ipc: 7C 07D 241/20 B Ipc: 7C 07D 277/82 B Ipc: 7C 07D 401/14 B Ipc: 7C 07D 401/04 B Ipc: 7C 07D 417/14 B Ipc: 7C 07D 417/04 B Ipc: 7C 07D 209/40 B Ipc: 7C 07D 213/74 B Ipc: 7C 07D 295/20 B Ipc: 7C 07D 211/70 B Ipc: 7A 61P 19/02 B Ipc: 7A 61P 11/06 B Ipc: 7A 61K 31/4418 B Ipc: 7A 61K 31/495 A |
|
17Q | First examination report despatched |
Effective date: 20050224 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20050707 |